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Abstract 
Though the management of diabetes is widely documented in scientific literature, little is 
published about how hypoglycemia is managed by family physicians.  The objective of this 
study was to create a measurement for family physician clinical inertia in managing 
hypoglycemia, and to determine family physicians’ characteristics associated with clinical 
inertia. The design was a secondary analysis of the data provided by 162 family physicians 
from the Canadian InHypo-DM Study.   The outcome for this thesis was a score for 
physician clinical inertia. The methods applied were exploratory factor analysis, bivariate 
analysis and multiple linear regression. Results showed no statistically significant 
differences in clinical inertia score for any of the independent variables. This study 
provides evidence that clinical inertia in management of hypoglycemia is not associated 
with family physicians’ characteristics. Further testing this score will provide more 
information on aspects of clinical inertia and its role in the management of hypoglycemia.  
Keywords 
Hypoglycemia Management in Family Physicians, Clinical Inertia in Hypoglycemia 
Management, Clinical Inertia in Family Physicians, Diabetes in Primary Care, 
Hypoglycemia, Clinical Inertia, InHypo-DM, Exploratory Factor Analysis.  
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Preface  
“Confucius, Buddha, Jesus and Muhammad would have been bewildered if you told them 
that in order to understand the human mind and cure its illnesses  
you must first study statistics.”  
The Discovery of Ignorance, Sapiens - A Brief History of Humankind 
Yuval N. Harari, 2014 
 
“Neither evidence nor clinical judgment alone is sufficient.  Evidence without judgment can 
be applied by a technician. Judgment without evidence can be applied by a friend. But the 
integration of evidence and judgment is what the healthcare provider does in order to 
dispense the best clinical care.”  
Hertzel Gerstein, 2012 
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Chapter 1  
1 Overview 
Medical knowledge advances at a fast pace, however some issues remain a perplexing 
challenge.  Even health problems that are old subjects to medical research and are quite 
familiar to the medical community, such as diabetes, present intriguing limitations in 
everyday clinical practice.   
This thesis explores the factors that may contribute to the relationship between management 
of hypoglycemia and physician clinical inertia.  The starting point for this study was 
provided by a recent Canadian nation-wide study on hypoglycemia in diabetes.  Data from 
family physician respondents who participated in that study were analyzed for this study. In 
this first chapter, a brief overview of the steps taken to explore this relationship is laid out.   
Chapter two reviews the literature on: diabetes and its relevance in primary care medicine; 
hypoglycemia management and recent updates; and clinical inertia.  This chapter provides 
preliminary concepts and establishes the current facts, guidelines and definitions for these 
topics.    
The next section, chapter three, describes the objectives and methodologic approaches of 
both the original InHypo-DM study and the subsequent secondary analysis conducted for 
the purpose of addressing the objectives of this thesis. The steps taken in the analysis of the 
original InHypo-DM study Healthcare Provider data set are explained.  The sequence of 
tests and procedures applied to achieve the study objectives is presented. 
The results for the analysis conducted are presented in chapter four.   
Chapter five reflects upon the findings of this study as to where they differ from the 
existing knowledge, where they confirm the current knowledge, and where those findings 
are novel and add to the existing knowledge of clinical inertia in hypoglycemia 
management in primary care.  Recommendations for future research are presented in this 
concluding section. 
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Chapter 2  
2 Diabetes, Hypoglycemia and Clinical Inertia 
2.1 Diabetes  
Diabetes and its related problems are frequent reasons for patient-physician encounters in 
primary care worldwide.  One of the issues that requires special attention from family 
physicians is the risk and occurrence of hypoglycemia in their patients with diabetes on 
insulin and/or secretagogues.  The ability to appropriately identify and manage this 
medication-related adverse event is a central competence of diabetes care.  Guidelines 
provide evidence-based recommendations to the fundamentals of diabetes management, 
and the exemplar physician is capable of individualizing treatment to best achieve patient`s 
target and well-being accordingly. Literature on family physician’s awareness, actions and 
attitudes towards hypoglycemia and appropriate treatment and intervention in primary care 
is substantially limited. 
  Diabetes Prevalence  
"Diabetes is one of the largest health emergencies of the 21st century" concluded the latest 
report of the International Diabetes Federation (IDF).1 It is estimated that Diabetes Mellitus 
(DM) affected 415 million adults ages 20 to 79 in 2015 worldwide and another 318 million 
persons have impaired glucose intolerance and are at a higher risk of developing type 2 
diabetes (T2DM).  Diabetes, particularly T2DM, is one of the most common chronic 
diseases in nearly all countries, and continues to increase in numbers and significance, 
particularly in developing nations. The Brazilian Health Ministry detected in 2018 that the 
incidence rate of DM increased by 61.8% in the last 10 years, rising from 5.5% of the 
population in 2006 to 8.9% in 2016.2   
Following the global trend, Canada’s rates of DM are also rising. It is estimated that an 
increase of 44% will be observed between 2015 to 2025 in the prevalence of DM among 
Canadians. Diabetes is the leading cause of blindness, end stage renal disease and non-
traumatic amputation in Canadian adults.3  
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Possible reasons for this DM epidemic include economic development and urbanization 
that lead to rapid cultural and social changes in traditional lifestyles characterized by 
reduced physical activity, ageing populations, increased urbanization, industrialized diet 
with increased sugar consumption and low fruit and vegetable intake, and consequently, 
increased obesity.1  
Globally, one in every 11 adults (8.8%) has DM and half of these are unaware of it1.  In 
high-income countries, approximately 87 to 91% of all people with diabetes are estimated 
to have T2DM, 7% to 12% are estimated to have type 1 diabetes (T1DM) and 1% to 3% to 
have other types of DM1. 
2.2 Hypoglycemia  
 Definition  
Hypoglycemia is defined biochemically as blood glucose concentration less than 4.0 
mmol/L, or 70mg/dL.4 The Canadian Diabetes Association (CDA), now known as Diabetes 
Canada, recently published a more sophisticated definition in their Clinical Practice 
Guidelines (CPG),5 where hypoglycemia is defined by three components:  
• Development of autonomic or neuroglycopenic symptoms (Table 2-a);  
• Low plasma glucose level (<4.0 mmol/L for patients treated with insulin or insulin 
secretagogue); and  
• Symptoms responding to the administration of carbohydrate  
 4 
 
 
Table 2-a: Symptoms of Hypoglycemia 
 
Ref.: Yale, JF et al. Diabetes Canada. 2018 Clinical Practice Guidelines, Hypoglycemia. Can J Diabetes. 2018. Cryer, PE 
et al. Insulin Therapy and Hypoglycemia in Type 2 Diabetes Mellitus. Insulin 2007  
Hypoglycemia is clinically classified by the severity of symptoms in the hypoglycemic 
event and by the individual's ability to self-treat.  When blood glucose levels drop below 
3.3 mmol/L, most patients experience unpleasant neuroglycopenic or autonomic 
progressive symptoms (Table 2-a). The first is the result of brain deprivation of glucose, 
leading to confusion, sensation of warmth, weakness or fatigue, severe cognitive failure, 
seizure and ultimately, if not reversed, coma.  The latter are the result of the perception of 
physiologic changes caused by the autonomic nervous system's response to hypoglycemia, 
manifested as tremulousness, palpitations, anxiety, sweating, hunger, paresthesia.  This 
state of physiological discomfort forces the individual to seek an action that normally 
prevents or rapidly corrects clinical hypoglycemia.6 Most episodes of lower blood glucose 
are associated with excessive use of medication, dietary mistakes, and physical exercise7; 
decreased glucose absorption in gastroenteritis and vomiting; or decreased glucose 
production in liver disease and alcohol intoxication.8  
In mild to moderate events, the patient can manage hypoglycemia him/her self by 
identifying the characteristic symptoms and ingesting enough carbohydrates to elevate 
blood glucose. Severe hypoglycemia happens when the patient is unable to identify the 
characteristic symptoms and/or is incapable of resolving the problem, needing assistance 
from others to recover.9 The severity of hypoglycemia is defined by clinical manifestations 
and consequences listed in Table 2-b.5  
Neurogenic 
(autonomic)
Neuroglycopenic 
Trembling 
Difﬁculty 
concentrating 
Palpitations Confusion 
Sweating Weakness 
Anxiety Drowsiness 
Hunger Vision changes 
Nausea Difﬁculty speaking 
Tingling Headache Dizziness
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Table 2-b: Severity of Hypoglycemia  
Mild: Autonomic symptoms are present. The individual is able to self-treat. 
Moderate: Autonomic and neuroglycopenic symptoms are present. 
The individual is able to self-treat. 
Severe: Unconsciousness may occur. Plasma glucose is typically <2.8 mmol/L. The Individual 
requires assistance of another person to treat. 
Ref.: Yale, JF et al. Diabetes Canada. 2018 Clinical Practice Guidelines, Hypoglycemia. Can J Diabetes. 2018. 
The American Diabetes Association (ADA) recently revised their definitions for 
hypoglycemia10.   
Table 2-c presents elements that characterize clinical hypoglycemia. 
 
Table 2-c: Classification of Hypoglycemia  
Level Glycemic Criteria Description 
Glucose alert value  
(level 1) 
70 mg/dL (3.9 
mmol/L) 
Sufficiently low for treatment with 
fast-acting carbohydrate and dose 
adjustment of glucose-lowering 
therapy 
Clinically significant 
hypoglycemia 
(level 2) 
54 mg/dL (3.0 
mmol/L) 
Sufficiently low to indicate serious, 
clinically important hypoglycemia 
Severe hypoglycemia 
(level 3) 
No specific glucose 
threshold 
Hypoglycemia associated with 
severe cognitive impairment 
requiring external assistance for 
recovery 
Ref.: Diabetes Care - Standards of Care, Hypoglycemia, 2019 Suppl.1 S67 American Diabetes Association 
 Relevance 
Hypoglycemia is commonly associated with people with T1DM, but is also seen in T2DM 
patients managed by insulin and/or, sulfonylureas.5 Ratzki-Leewing et al11 analyzed the 
results of the largest real-world investigation of hypoglycemia epidemiology in Canada and 
affirmed that the incidence of hypoglycemia among adults with DM taking insulin and/or 
insulin secretagogues is higher than previously thought.  In their paper, the authors stated 
that, while 83.0% of people with T1DM reported having experienced at least one 
hypoglycemic event with an overall annualized hypoglycemia rate of 58.1 events per 
person-year, 62.0% of T2DM individuals experienced at least one hypoglycemia event at a 
rate of 30.4 events per person-year.  
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Hypoglycemia is less common in the early stages of T2DM because the glucose plasma 
counter-regulatory mechanisms tend to be preserved in these patients.  However, if patient 
management at this stage of diabetes includes oral hypoglycemic agents, such as 
secretagogues, or those on an insulin regimen, hypoglycemia can occur and therefore can 
be an important complicating factor in efforts to achieve tighter glycemic control. 
The United Kingdom Prospective Diabetes Study (UKPDS)12, was a landmark study in the 
treatment of T2DM that has influenced standards of care and treatment guidelines 
throughout the world.  That study found that severe hypoglycemia occurred in 11% of 
subjects on aggressive therapy over a 6-year follow-up period.  The Diabetes Outcomes in 
Veterans Study (DOVES)13, was another important study which identified clinical and 
behavioral factors associated with glucose variability in T2DM. It reported 5.5% of subjects 
experienced severe hypoglycemia over the 8-week observation period7.  One author has 
boldly stated that hypoglycemic events are nearly inevitable in patients if tight glycemic 
control is to be achieved.15  
Life-threatening, severe hypoglycemia in T2DM patients was believed to be a relatively 
infrequent event7, but a recent national epidemiologic study in Canada has challenged that 
idea. Ratzki-Leewing et al found that, in the InHypo-DM questionnaire answered by 
patients with diabetes reporting any type of hypoglycemic event, “the incidence rate of 
severe hypoglycemia was approximately 37% higher in people with T2DM” than that found 
among those respondents who were T1DM.11 page 6  
 Risk Factors for Hypoglycemia  
The odds of experiencing hypoglycemia in people with T2DM have been measured by 
Reichert et al14 and the authors found that they were highest among younger adults, those 
with poor glycemic control, those who took multiple daily injections of insulin, and those 
who lead busy lives (working full time and/or shift work).  
Type 2 DM patients are at a higher risk of experiencing severe hypoglycemia when the 
following factors are present: advancing age, severe cognitive impairment, poor health 
literacy, food insecurity, hypoglycemia unawareness, prolonged duration of insulin therapy, 
renal impairment and neuropathy.4 Another large landmark study for T2DM patients with 
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elevated risk for cardiovascular disease, the Action to Control Cardiovascular Risk in 
Diabetes trial (ACCORD)16, identified additional risk factors for that population including: 
female gender, African-American race and less than high-school education.17   
A compilation of major risk factors cited in Diabetes Canada’s Clinical Practice Guideline 
(CPG) for severe hypoglycemia is presented in Table 2-d. 
Table 2-d: Risk factors for Severe Hypoglycemia  
Diabetic Patients presenting with these conditions are 
at risk for severe hypoglycemic events 
 
 Prior episode of severe hypoglycemia 
Current low glycated hemoglobin (<6.0%) 
Hypoglycemia unawareness 
Long duration of insulin therapy 
Autonomic neuropathy 
Low economic status 
Food insecurity 
Low health literacy 
Cognitive impairment 
Adolescence 
Long duration of Insulin therapy 
Presence of complications (renal impairment or 
neuropathy) 
Persons unable to detect and/or treat mild  
hypoglycemia on their own  
Ref.: Yale, JF et al. Diabetes Canada. 2018 Clinical Practice Guidelines, Hypoglycemia. Can J Diabetes. 2018. 
 
In the early stages of T2DM, when physiologic defenses against hypoglycemia are intact, 
the mechanisms for preventing the lowering of blood glucose (down regulation of insulin 
secretion in β-cell and increase in α-cell glucagon or epinephrine secretion) support 
euglycemic levels. Over the course of the illness, with progressive beta cell decline 
hyperglycemia often becomes an issue that patients struggle with. Impairment of 
sympathetic neural response occurs in consequence of sustained hyperglycemia. At this 
stage many individuals develop a condition where there is an impairment of the ability to 
perceive the warning symptoms of hypoglycemia, or even the loss of sympathetic neural 
response.  This impairment of hypoglycemia awareness is mediated by an "adaptation of 
the hormonal counter-regulatory response towards low blood glucose levels"15 page 229 and it 
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consists of a reduced ability to perceive the "warning symptoms" due to a lower threshold 
of these symptoms.  A destructive cycle of hypoglycemia induced by previous 
hypoglycemia is a critical predictive risk factor for severe hypoglycemic episodes15. This 
poses a challenge for aggressive treatment regimens that put patients at risk for 
hypoglycaemia, for example patients on insulin and/or secretagogues.   
In the ADA’s recently reviewed guidelines, insulin-treated patients with hypoglycemia 
unawareness or an episode of clinically significant hypoglycemia (< 3.0 mmol/L) should be 
advised to raise their glycemic targets to strictly avoid hypoglycemia for at least several 
weeks to partially reverse hypoglycemia unawareness and reduce risk of future episodes.18  
According to Heller, strategies to diminish the risk of hypoglycemia from the provider’s 
stand point should be guided by three principles19: 
• Individual targets adjusted for patient’s vulnerability to hypoglycemia;  
• Structured education and training for people with diabetes; and 
• Team care that is alert to potential problems with hypoglycemia. 
 Glycemic Goals 
Evidence-based guidelines compels the primary care physicians (PCP) to set customized 
targets for each patient’s blood glucose levels after considering several factors.  Intensive 
glucose control, lowering glycated hemoglobin (A1C) values to ≤7% in both T1DM and 
T2DM, provides strong benefits for prevention of microvascular complications and, if 
achieved early in the disease, likely provides a significant macrovascular benefit, especially 
as part of a multifactorial treatment approach. More intensive glucose control, A1C ≤6.5%, 
may be sought in patients with a shorter duration of diabetes, no evidence of significant 
cardiovascular disease and longer life expectancy, as long as this does not result in a 
significant increase in hypoglycemic events. An A1C target ≤8.5% may be more 
appropriate in T1DM and T2DM with limited life expectancy, higher level of functional 
dependency, a history of severe hypoglycemia, advanced comorbidities, and a failure to 
achieve established glucose targets despite treatment intensification.20  
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According to guidelines, if lifestyle and dietary modifications fail to achieve target A1C 
after two to three months of adjustments, it is recommended that antihyperglycemic 
pharmacotherapy should be initiated.  Unless contraindicated or the patient is intolerant, 
metformin should be the initial agent of choice.  Additional antihyperglycemic agents 
should be selected on the basis of clinically relevant issues and always tailored to each 
patient’s individual characteristics and glycemic target, such as: contraindication to drug, 
glucose lowering effectiveness, risk of hypoglycemia and effect on body weight.  Timely 
adjustments to, and/or additions of other antihyperglycemic agents should be made to reach 
target A1C within three to six months.  In patients with marked hyperglycemia (A1C 
≥1.5% above individualized target), antihyperglycemic agents should be initiated along 
with lifestyle modifications, and consideration should be given to initiating combination 
therapy with two agents, one of which may be insulin.21  
 Hypoglycemia-inducing pharmacologic agents 
Glucose lowering agents used to treat T2DM can contribute to a patient’s risk for 
hypoglycemia, with some agents more likely to produce hypoglycemia than others.  
Biguanides (e.g. metformin) lower blood glucose by mechanisms other than increasing 
blood level of insulin, working in a glucose-dependent manner.  Metformin, for example, 
decreases hepatic glucose production and increases insulin sensitivity.  This group of agents 
are considered at low-risk for causing hypoglycemia and unlikely to induce hypoglycemia 
when used as monotherapy.8 The Diabetes Canada 2018 CPG recommends metformin as a 
first-line therapy for individuals without metabolic decompensation. However, if metabolic 
decompensation is present, insulin is the choice for initial treatment.3  
Secretagogues, a common choice for second-line therapy, stimulate insulin secretion from 
pancreatic β-cells in a glucose-independent manner, and thus, are associated with a high-
risk of hypoglycemia.  Recent studies with practice-changing evidence have proven that in 
adults with T2DM with clinically significant cardiovascular disease in whom glycemic 
targets are not met, the second antihyperglycemic agent to be added should be one with 
demonstrated cardiovascular outcome benefit.  Some SGLT-2 inhibitors (i.e. empagliflozin 
and canagliflozin) have shown such benefits without increasing risk of hypoglycemia.21 
Other antihyperglycemic agents, such as glucagon-like peptide-1 (GLP-1) receptor 
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agonists, have also shown benefits for T2DM patients with cardiovascular risk factors and 
unmet A1C targets21 (i.e. liraglutide).    
Insulin is generally considered as the third-line therapy and the group of agents most likely 
to cause hypoglycemia amid the medications in the high-risk category.22 A combination of 
oral antihyperglycemic and insulin often effectively control glucose levels.  The choice of 
insulin and insulin regimen should take into consideration multiple type-specific 
advantages and disadvantages and patient’s needs, preferences and context.   
Current evidence from a systematic review and meta-analysis by Edridge et al shows that 
hypoglycemia is considerably prevalent amongst people with T2DM, particularly for those 
on secretagogues or insulin.23  
 Treatment of Hypoglycemia 
Treatment of hypoglycemia can be easily accessed in most settings.  Patient education is 
essential.  Orientation may include discussing with patient a plan of action, recognizing 
hypoglycemic symptoms and identifying available sources of glucose.   
Treatment aims at restoring normal blood glucose quickly and safely, avoiding 
overcorrection.  Diabetes Canada CPG suggests that 15g of glucose (equivalent to 3 
teaspoons of table sugar; 1 tablespoon of honey; or ¾ cup of orange juice) is efficient in 
raising glycemia by 2.1mmol/L within 20 minutes.  Glucagon 1mg subcutaneously or 
intramuscularly produces significant blood glucose elevation (up to 12mmol/L) in 60 
minutes. Recent alcohol consumption and advanced hepatic disease may impair correction 
of blood glucose level.5  
Clinical strategies and revised practice guidelines that accentuate the need to balance 
effective glycemic control against the risk of hypoglycemia are emerging regularly.18   
Adding to this, newer and safer antihyperglycemic treatments and pharmacologic 
combinations are becoming more readily available.  However, despite these facts, the 
current burden of hypoglycemia in the real-world context still exists and has been 
underestimated, especially concerning severe hypoglycemia in T2DM.11  
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In the introduction of the 2018 Diabetes Canada CPG, the author advises: “People with 
diabetes are a diverse and heterogeneous group; therefore, it must be emphasized that 
treatment decisions need to be individualized. Guidelines are meant to aid in decision 
making by providing recommendations that are informed by the best available evidence. 
However, therapeutic decisions are made at the level of the relationship between the 
healthcare professional and the patient. That relationship, along with the importance of 
clinical judgement, can never be replaced by guideline recommendations.”3 The 
cooperation that derives from a solid, genuine patient-provider relationship is indeed of 
immense clinical value.  Yet, sacrificing medical evidence, in the form of clinical 
guidelines or expert panels for the sake of individualizing care inattentively is not aligned 
with the principles of the Patient-Centered Clinical Method24 and such an attitude must not 
be mistaken for patient-centeredness. 
Recommendations from the 2018 CPG on hypoglycemia are listed in Appendix A. 
 Hypoglycemia Management in Primary 
Healthcare 
Management of the patient with DM embodies the spirit of primary care medicine.  
Because of the chronic, progressive, and potentially disabling nature of this illness, PCP 
should be at the cornerstone of diabetes care.  This gate-keeping position allows 
professionals to screen high-risk patients for diabetes, initiate treatment, improve 
hyperglycemia, monitor and fine-tune pharmacologic therapies, and detect and manage 
microvascular and macrovascular complications. While patients with complex insulin 
regimens, or at risk for severe hypoglycemia, or complications often need to be referred to 
specialists to assist in management, 90% of patients with diabetes can successfully be 
managed in a primary care setting.25   
Diabetes is an increasingly common health condition, currently affecting one in every 11 
adults globally.26 It is estimated that three-quarters of people with diabetes live in low and 
middle-income countries1. Ninety percent of these patients have T2DM7, and most these 
individuals are cared for by non-specialist PCP.19 In Brazil, for example, diabetes is among 
the five major health problems managed by PCP in community health centers.27 Yet, this 
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fact also applies to developed nations such as Canada and the United States, where the bulk 
of diabetes patients are cared for by PCP.11, 28, 29  
Diabetes is a chronic and complex clinical condition, perhaps more common and complex 
in the real-world context PCP face daily than what trial-based settings have been able to 
show.30 This idea is supported by the findings of a study conducted by Bachimont in 2006 
which identified that PCP were aware of the guidelines, however they found that these 
guidelines sometimes disconnected from everyday practice.31  
Heller argues that PCP are less confident/less knowledgeable about the risks of insulin 
management and hypoglycemia when compared to specialists and thus may not be actively 
and adequately assessing and managing the risk of hypoglycemia for each patient.19  
Since most of the care of people with diabetes takes place in the primary care setting, there 
has been a shift toward delivering diabetes care in the primary care setting using the 
chronic care model.32 This model comprises an arrangement of the health system in which 
the primary care provider is properly trained and well-articulated with specialists and other 
actors of the healthcare system and community. There is evidence that the chronic care 
model is an effective and efficient model of care for DM. 32, 33   
Dovey also argues that an essential characteristic of primary care is the customization of 
care to the individual patients' needs, values, and preferences across a broad spectrum of 
medical care. That author states about primary care practices: “Its diversity, scope and 
variation in structure and infrastructure may offer more opportunity for error than more 
highly regulated and procedure-oriented hospital-based care.”34  
Though the management of diabetes and its complications are widely investigated and 
documented in scientific literature, little is published about how one important component 
of DM, hypoglycemia, is managed in the primary care setting, and even more scarce is the 
evidence around the factors that affect physician hypoglycemia management behavior and 
key PCP knowledge gaps.  
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 The Care Gap 
Numerous studies have shown that hypoglycemia is an important clinical concern for 
T1DM patients and those who are T2DM on insulin and/or secretagogue agent therapy.  In 
general, hypoglycemia presents a barrier to starting and adjusting treatment and a challenge 
in long-term adherence35, 36.  Despite the evidence that tight glycemic control reduces 
morbidity and mortality of DM, a significant percentage of patients do not reach treatment 
goals. In the United States only 40-60% of T2DM patients reach treatment goals.  In 2009, 
The British National Health System (NHS), reported that two-thirds of T2DM patients 
achieved the goal of 7.5% glycated hemoglobin (A1C).  In Canada, the Diabetes Mellitus 
Status survey35 highlighted the persistent treatment gap associated with the treatment of 
T2DM and the challenges faced by primary care physicians to gain glycemic control in 
these patients. Some evidence shows that the fear of a new hypoglycemic episode can 
undermine patient compliance to rigorous treatment goals and lead to poor self-
management of the disease.36, 37, 38, 39, 40   
Proper management should include a comprehensive approach and collaboration between 
patients, primary care, and specialist care when appropriate.3 In North America, most of 
chronic illness care, including diabetes as noted previously, occurs within the primary care 
setting.29 In Canada, there is a care gap between the clinical goals outlined in evidence-
based guidelines for diabetes management and real-life clinical practice.28  
In summary, despite the recognition of the importance of identifying and managing 
hypoglycemia as part of an overall diabetes management strategy, very little is known 
about the factors that influence family physician’s attitudes and behavior in managing 
hypoglycemia.  This study will use newly available survey data from family physicians in 
Canada to explore this prominent issue. 
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2.3 Clinical Inertia 
 Overview 
Delays in correcting prescribed treatment in T2DM patients when treatment fails to achieve 
optimal glycemic control, occurs commonly in primary care settings. A substantial 
proportion of people remain in poor glycemic control for several years before proper 
adjustment of targets and pharmacologic treatment is initiated 41. These delays or inertia on 
the part of physician to fine-tune treatment in the presence of hypoglycemia is perplexing.   
 Definition 
The term clinical inertia was coined by Phillips in 2001.42  It refers to the situation when 
there is recognition of the clinical problem (e.g. a history of hypoglycemic episodes), but 
no initiative to act upon it (e.g. reticence to adjust targets or tardiness to review insulin 
therapy).41, 42.  O’Connor et al postulate three classes of factors leading to inertia: those 
related to the patient, those related to the health system and factors related to the physician.  
They estimate that these three factors contribute 30%, 20% and 50% respectively to the 
phenomenon of clinical inertia.44 Factors related to the patient that are believed to be 
associated with clinical inertia include denial or misconception about the disease and its 
seriousness; medication nonadherence due to avoidance of expenses and/or side effects; 
and resistance to adopting lifestyle adjustments that could lead to better health-related 
outcomes. Factors of the system include availability of technology that optimizes clinical 
reasoning and prompts specific clinical decision support; organization and 
planning/prioritizing office visits according to risk, complications, results of tests; active 
outreach support; availability of continuous medical education. Operationally, the 
definition of clinical inertia is quite complex and all of these factors may be in play 
simultaneously.44  
True clinical inertia may be considered a case of medical error by omission.  Dovey 
conducted a study to understand the nature of medical errors from the perspectives of 
family physicians.34   Family physicians were asked to describe deleterious events which 
should not have occurred and which made them think: “this should not happen in my 
practice, and I never want this to happen again”.  He found that clinical inertia, in a broader 
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sense, was not mentioned as being part of the “taxonomy” of medical errors34. In contrast, 
two other authors, also researching behavior in diabetes treatment, have clearly referred to 
physician behavior falling under clinical inertia as “medical errors”.44, 45   
True clinical inertia must be distinguished from watchful waiting.  This attitude is a 
carefully thought out decision to withhold action.  Gerard Reach, in his book Clinical 
Inertia46, argues that the physician behavior falls under this phenomenon of clinical inertia 
if, and only if: 
1.    a Guideline (G) exists, explicit or implicit       
2.    the doctor (D) knows the Guideline (G)       
3.    the doctor (D) thinks that this Guideline (G) applies to the patient (P)       
4.    the doctor (D) has the resources to apply the Guideline (G)       
5.    conditions 1–4 have been met, yet the doctor (D) does not follow the Guideline (G) in 
the case of the patient (P). 46 Page 10      
  
Clinical inertia has been recognized as an important barrier contributing to inadequate 
management of chronic diseases, particularly in the context of those with asymptomatic 
conditions such as diabetes, hypertension, lipid disorders, where treatment decisions are 
generally influenced by pondering evidence-based clinical outcomes.47  
 Clinical Inertia in Primary Care 
A review of the literature concerning diabetes and clinical inertia reveals some relevant 
research concerning management of hyperglycemia and its associations with physician 
inertia in primary care settings.  However, literature addressing therapeutic inertia in 
management of DM related hypoglycemia in primary care, to the extent of this researcher’s 
knowledge, is all but non-existent.  Therefore, it is only possible to conceptualize clinical 
inertia for DM care by examining the literature on clinical inertia in hyperglycemia 
management.     
Research with family practices in Ontario, Canada, found that insulin was underused by 
PCP in patients with T2DM, even though early addition of insulin has long been an 
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efficient way to quickly and safely achieve glycemic targets and that its use has been 
recommended by national and international guidelines.28 Another study in Ontario, this one 
by Shah et al, identified that “fewer than one-half of patients with high A1C levels had 
intensification of their medications, regardless of the specialty of their physicians.”48 
A nation-wide study in Croatia aimed at understanding clinical inertia in DM management 
in primary care found that clinical inertia was present in 57.7% of all clinical encounters.49 
They concluded that 100% FPs were clinically inert with some patients while 9% of FPs 
were clinically inert with all DM patients. Clinical inertia significantly increased in 
correspondence with increasing A1C levels. Also, this research found that male family 
physicians were more likely to be clinically inert than female family physicians. Another 
researcher identified characteristics of the physicians who were most likely to follow 
guidelines, and therefore less inclined to clinical inertia: female, recently completed 
medical studies, frequently used a computer and worked in groups.50  
Another interesting aspect of physician behavior that could lead to clinical inertia is the 
impact of competing demands in the patient-physician encounter.  Parchman51 investigated 
the relationship between clinical inertia and competing demands in primary care.  This 
study found that among patients with an A1C level greater than 7%, each additional patient 
concern was associated with a 49% reduction in the likelihood of a change in medication. 
The author concluded that the concept of clinical inertia is limited and does not fully 
characterize the complexity of primary care encounters.  
Ziemer et al. believe that clinical inertia among PCPs is due to limited exposure to 
education on target-oriented treatment and indications to treatment intensification.52  Zafar 
et al. listed other factors that explain clinical inertia, some of which are directly related to 
the primary care physician.41 He believes that the phenomenon of clinical inertia should be 
analyzed apart from patient-related issues: i.e., it is essentially a problem of the physician 
and the health care system not taking proper action in favor of the patient (Figure 2-b). 
While patient non-adherence may potentiate clinical inertia on the part of the PCP, failure 
to improve therapy is essentially related to physician and delivery system issues.43     
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Figure 2-a: Clinical Inertia in DM Care 
 
 Theoretic Models of Clinical Inertia 
The determinants that potentially explain clinical inertia are numerous and their interactions 
are sometimes complex and difﬁcult to interpret. For this reason, the construction of 
theoretical models is needed to allow a more didactic and comprehensive view.   Reach46 
mentions five theoretical explanatory models of clinical inertia:  
• Knowledge-Attitude-Behavior-Result Model by Cabana et al (1999)53;  
• Awareness-Agreement-Adoption-Adherence by Pathman et al (1996)54;  
• Symmetrical Model involving Physician and Patient by Kim et al (2003)55;  
• Physician Guideline Compliance Model by Maue et al (2004)56; and  
• The Regulatory Focus Theory Model by Higgins et al (1997)57. 
Cabana argues that physician adherence to clinical guidelines is critical in translating 
recommendations to improved patient health outcomes.  In this comprehensive framework 
review, the author dissects the process of decision making in guideline adherence and 
Healthcare 
System
Community and Culture
Racial and ethnic disparities
Variation in healthcare settings
Primary 
Care 
Physician
Perception of improvement
Knowledge and Experience
Clinical traditions
Non-adherence to guidelines
Ineffective communication
Patient Atitudes and beliefs
Socio-economic status
Non-compliance to diet and medication
Acute and terminal illness 
Ref.: Zafar A, et al. Clinical Inertia in management of T2DM. Primary Care Diabetes, 2010  
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creates a theoretical framework for the baseline barriers that may undermine it and 
contribute to the phenomenon of physician clinical inertia.   
This model is based on the premise that the mechanism of action by which improved 
patient care is achieved occurs in steps, as postulated by Woolf in 199358.  Before a practice 
guideline can affect patient outcomes, it must first affect physician knowledge, then 
attitudes, and finally behavior. Guidelines have been considered effective not only by 
measuring the outcomes, but also if they improve knowledge, making clinicians aware of 
the recommendations; attitudes, getting clinicians to agree with and accept the 
recommendations as a new standard of care; and behavior, getting clinicians to change 
practice patterns to conform with the guidelines.58 Although behavior can be modified 
without knowledge or attitude being affected, behavior change based on influencing 
knowledge and attitudes is probably more sustainable than indirect manipulation of 
behavior alone.53  
Clinical inertia is essentially a pattern of behavior. This thesis focused on the creation of a 
clinical inertia scale comprised of the elements of the actual inertia behavior in practice, 
and examined potential factors that contribute to inertia.    
 Barriers to Behavior Change 
Table 2-e synthesizes Cabana’s rational for the barriers affecting physician’s ability to act 
upon a clinical problem: 
Table 2-e: Barriers to Behavior Change 
Intrinsic Knowledge Awareness The expanding body of research makes it difficult for 
any physician to be aware of every applicable 
guideline and critically apply it to practice. 
Familiarity Casual awareness does not guarantee familiarity of 
guideline recommendations and the ability to apply 
them correctly.  Lack of familiarity is more common 
than lack of awareness. 
Attitude Agreement Physicians may not agree with a specific guideline or 
the concept of guidelines in general. 
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Behavior Self-efficacy It is the belief that one can actually perform a behavior. 
It influences whether a behavior will be initiated and 
sustained despite poor outcomes. 
Outcome 
Expectancy 
Is the expectation that a given behavior will lead to a 
particular consequence. If a physician believes that a 
recommendation will not lead to an improved outcome, 
the physician will be less likely to adhere. 
Inertia of 
Previous 
Practices 
Physicians may not be able to overcome the inertia of 
previous practice, or they may not have the motivation 
to change behavior. 
Extrinsic Guideline  Physicians are less likely to adhere to guidelines they 
perceive as not easy to use or not convenient, or that 
modify an established behavior (when compared to 
ones that introduce a new behavior). 
Patient  The inability to reconcile patient preferences with 
guideline recommendations is a barrier to adherence. 
Environment/System  Adherence to practice guidelines may require changes 
not under physician control, such as acquisition of new 
resources or facilities. 
Ref.: Cabana MD, Rand CS, Powe NR, Wu AW, Wilson MH, Abboud P-AC, Rubin HR. Why don’t physicians follow 
clinical practice guidelines? A framework for improvement. JAMA. 1999; 282:1458–67. 
 
 The Challenge 
Though the management of diabetes and its complications are widely investigated and 
documented in scientific literature, there is insufficient evidence about how hypoglycemia 
is managed in a primary care setting.  In addition, it seems that what is considered in the 
literature as clinical inertia (that is, physicians not taking action in clinical circumstances 
that current guidelines clearly indicate action is recommended) is an acknowledged event in 
primary care medicine and that its frequency and consequences make it a major public 
health problem. The objective of this thesis was to develop a measure of clinical inertia 
specific to hypoglycemia and, by using that measure, gain an understanding about the 
factors that influence clinical inertia behavior in family physicians in the management of 
hypoglycemia.  
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Chapter 3  
3 Methodology 
This thesis was a secondary analysis of a sub-set of data collected in the project entitled 
“UnderstandINg the impact of HYPOglycemia on Diabetes Management: A Survey of 
Perspectives and Practices” (InHypo-DM Study).   
3.1 Study Objectives 
This study had two objectives.   
1. The first objective was to determine the factor structure for the construct of clinical 
inertia around family physicians’ behavior in managing hypoglycemia in their 
diabetic patients, in the primary care setting.   
2. Should a robust factor structure be found for clinical inertia, the second objective 
was to determine if there was a correlation between physician clinical inertia and 
family physician characteristics.  
3.2 Study Design 
This study was an exploratory factor analysis using secondary data from a cross-sectional 
family physician self-reported survey about hypoglycemia management.  Data was 
obtained from the InHypo-DM Study. 
3.3 Data Source: The InHypo-DM Study 
 InHypo-DM Study Overview 
The InHypo-DM Study was the largest hypoglycemia research program conducted in 
Canada to date.11 This study was initiated across Canada in 2014 and data analysis is 
ongoing to the present date.  The data used in this thesis were collected from February to 
April 2016.   It was an investigator-initiated research study conducted by Dr. Stewart Harris 
and collaborators at Western University. It explored clinical and personal perspectives, and 
practices and behaviors related to hypoglycemia in diabetes, as well as factors influencing 
hypoglycemia management from the perspectives of three distinct populations: patients 
with DM, people who have a significant other with DM, and healthcare providers (HCP).   
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 InHypo-DM: Methodology 
The InHypo-DM Study used a mixed-methods approach with quantitative and qualitative 
methods used at distinct stages of the project.  Initially, a comprehensive literature review 
was conducted and 87 questionnaires were identified, from which 2035 questions were 
extracted and categorized by specific domains.  
 InHypo-DM: Theoretical Domains Framework 
Tool 
A validated tool, the Theoretical Domains Framework (TDF)59, was employed in the 
development of interview guides for a sample of key informants: patients with DM (DM), 
their significant others (SO) and healthcare providers (HCP).  Given the complexity of the 
management of hypoglycemia, and the limited understanding of it thus far, the TDF tool 
became especially useful for determining the psychosocial, situational, organizational, and 
environmental determinants of behavior.  Qualitative interviews with DM, SO and HCP 
were conducted to explore their knowledge, experiences, and opinions regarding 
hypoglycemia management.   
 InHypo-DM: Questionnaires 
Questionnaires for the three population groups (DM, SO, HCP) were developed using the 
knowledge from the literature review and the key informant interview, while guided by the 
TDF.  Responses were formulated using 5-point Likert Scales. These questionnaires were 
piloted for feedback on relevance, clarity, and quality of response options.   
The HCP questionnaire (Appendix B) was developed to explore factors that impact HCP 
potential to effectively help people with diabetes manage hypoglycemia and included a 
socio-demographic and professional profile segment (section 9) and eight sections on 
practices and opinions about hypoglycemia management: 1) Knowledge, 2) Capability, 3) 
Practice, 4) Support, 5) Views, 6) Effects of work life and 7) Effects of social relationships, 
and 8) Worry/frustration.  Respondents included Endocrinologists, Family Physicians, 
Nurse Practitioners, Registered Nurses, Dietitians, and Pharmacists who provide diabetes 
care.   Appendix  contains the entire In-Hypo DM HCP questionnaire. 
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 InHypo-DM: HCP Sampling  
A total of 9163 e-mails were sent with an invitation to participate in the study and a link to 
the HCP questionnaire.  The sources for the distribution of the online survey were: a) a 
panel of physicians and pharmacists who provide diabetes care administered by 
Professional Targeted Market (PTM), counting 5579 contacts, or 60.9%; and b) the 
professional section of the Canadian Diabetes Association registered diabetes educators and 
physicians/researchers (CDA), counting 3584 contacts, or 39.1%.  The sampling service 
utilized multi-source recruitment, quota sampling and quality monitoring. Those who fully 
completed the questionnaire totalled 671 respondents among physicians and other allied 
healthcare providers.  The diagram in Figure 3-a details the sampling steps:  
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Figure 3-a: Consort Diagram for the In-HypoDM Study, HCP sampling  
 
N= total number; PTM = Professional Targeted Marketing; CDA = Canadian Diabetes Association  
Ref.: Investigating the impact of hypoglycemia on diabetes management: A survey of perspectives and practices. 
(InHypo-DM Study) Final report phase I & II, 2016. 
 InHypo-DM: HCP Respondents – Descriptive 
Results 
The respondents included: physicians (28.9%) and other healthcare providers: nurse (nurse 
practitioners and registered nurses) (37.1%), dietitians (16.4%), and pharmacists (10.1%). 
The profile of HCP respondents overall was as follows: the majority were female (75%), 
the average age was 53 years, they were practicing for an average of 16 years, the majority 
(69.4%) practiced in an urban setting and the majority (65.7%) were Certified Diabetes 
Educators (CDE or, in this paper, also referred to as Diabetes Educator designation).   
Email invites n=9.163    
(5.579 PTM; 3.584 CDA)
No response 
n=7.613
Response n=889
Incomplete/Drop-
out n=218
Complete n=671
Nurse n=249 Physician n=194
Family Physician 
n=162
Diabetes Specialist 
Family Physician 
n=9
Endocrinologists 
n=14
Other n=9
Dietitian n=110 Pharmacist n=68 Other n=50
Hard-bounced 
n=661
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Respondents saw an average of 28 patients with diabetes per week and 15.7% of these 
people had been diagnosed with T1DM.  
One hundred and ninety-four physicians completed the questionnaire: 162 family 
physicians, 14 endocrinologists, 9 diabetes specialist family physicians, 4 internal medicine 
and 5 respondents from other medical categories. The physician respondents’ (28.9%) 
profile was: male (57%), average age of 56.7 years, few (6%) were Certified Diabetes 
Educators, practicing for an average of 26 years, in an urban setting (77.3%), seeing an 
average of 31 patients with diabetes per week.  Only 6% of the physicians were CDE.   
Table 3-a shows a comparison of HCP respondent profile and the physician respondent 
profile. 
Table 3-a: Comparison of Other Health Care Provider and Physician Characteristics 
 
N = total number; DM = Diabetes Mellitus; pt = patient 
Ref.: Investigating the impact of hypoglycemia on diabetes management: A survey of perspectives and practices. 
(InHypo-DM Study) Final report phase I & II, 2016. 
3.4 Sample 
The sample for this thesis consisted of the sub-set of 162 family physicians who completed 
the InHypo-DM HCP questionnaire.  
3.5 Variables 
  Dependent Variable 
The first objective of this thesis was to create a clinical inertia scale. The potential items for 
inclusion in the scale were the 13 questions in section 3 that asked family physicians about 
what they believed to be true about their actual practices and behavior.  The heading for 
this section of the questionnaire read: “These are questions about what you do when 
HCP 
Respondents 
(n=671)
Physician 
Respondents 
(n=194)
Sex (%) 75 57
Age in years (mean) 53 56.7
Diabetes Educator designation (%) 65.7 6
Years in practice (mean) 16 26
# DM pt/week (mean) 28 31
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helping your patients manage their hypoglycemia.  Remember that management refers to 
both treatment and prevention.  Please select the answer that you believe is true most of the 
time:”   
Table 3-b reproduces the 13 items in Section 3 from the questionnaire. The response 
categories in the 5-point Likert scale were: “Never”; “Rarely”; “Sometimes”; “Often”; and 
“Always”.    
Table 3-b: Potential Items for the Clinical Inertia Scale  
Section 3 – These are questions about what you actually do when helping 
your patients manage their hypoglycemia. Remember management refers to 
both treatment and prevention.  Please select the answer that you believe is 
true most of the time: 
 In general, 
Name of variable for 
this thesis 
10) …I make an effort to keep track of my patients’ progress with regard to 
managing their hypoglycemia. 
effort track progress 
11) …I advise my patients to increase the frequency of blood glucose monitoring 
when they are at increased risk for hypoglycemia. 
advice increase 
monitor  
12) …I make sure that I am prepared to help my patients manage their 
hypoglycemia. 
prepared to help  
13) …I am confident that I can help my patients manage their hypoglycemia even 
when there is little time. 
time management 
14) …addressing the specific appointment issue takes priority over discussing their 
hypoglycemia management.   
specific issue priority  
15) …helping my patients manage their hypoglycemia is something I do routinely. routine help 
16) …the way I help my patients manage their hypoglycemia is informed by current 
evidence and guidelines. 
guideline informed 
17) …I take the initiative to help my patients improve their hypoglycemia 
management. 
take initiative 
18) …I explain how to manage hypoglycemia to my patients. explain how manage 
19) …I discuss hypoglycemia-related guidelines regarding driving or operating 
heavy machinery with my patients. 
discuss guidelines 
20) …I solicit patients’ input when discussing their hypoglycemia management. solicit input 
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 Independent Variables 
The independent variables used in this analysis were:  
a) Age in years,  
b) Sex (male, female),  
c) Years in practice,  
d) Practice location (rural or urban setting),  
e) Canadian province where the practice was located (recoded into the following categories:  
Ontario (ON); Quebec (QU); Newfoundland (NL); Alberta (AB); Western/Prairie 
Provinces – British Columbia (BC), Manitoba (MB) and Saskatchewan (SK); and Maritime 
Provinces – Prince Edward Island (PEI), New Brunswick (NB) and Nova Scotia (NS).   
f) Practice type (response options in the questionnaire were Hospital, Family Health Team 
or Other.  The answers for the open-text option Other included: Family Health 
Organizations or Groups; Primary Care Network, solo/private office; Community Health 
Clinic/walk-in clinic, corporate clinic, military Clinic, long-term care and palliative 
facilities, and retirement homes. All responses were recoded as “Hospital”, “Team-based 
practice” and “non-Team based practice”),  
g) Diabetes Educator designation (yes or no),  
h) Country where the respondent obtained the most recent professional degree, (Canada or 
other) 
21) …I use motivational strategies to help my patients manage their hypoglycemia. motivational strategy 
22) …my professional liability, according to my specific regulatory body, directs 
the way I manage patients’ hypoglycemia. 
professional liability 
Ref.: Investigating the impact of hypoglycemia on diabetes management: A survey of perspectives and practices. 
(InHypo-DM Study) Final report phase I & II, 2016. InHypo-DM HCP questionnaire, Section 3 
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i) Mean number of diabetes patients the respondent physician usually sees in an average 
week (# DM pt/week),  
j) Personal diagnosis of diabetes (yes or no). 
3.6 Descriptive Analysis 
A descriptive analysis examined the distribution of all variables. The frequencies and 
percentages for the response for each of the 13 potential clinical inertia items were run, and 
missing values were identified. For the independent variables, the mean and standard 
deviation were calculated for age, years in practice and number of DM patients per week. 
For the remaining independent variables, sex, practice type, practice location, province of 
practice, country of medical degree, DM educator designation, and personal diagnosis of 
diabetes, frequencies and percentages were run. All analyses were conducted using SPSS 
statistics version 25.  
3.7 Exploratory Factor Analysis 
Exploratory Factor Analysis (EFA) was the chosen statistical technique to address the first 
objective of this study, to create a clinical inertia scale.  There are two main purposes or 
applications of factor analysis: data reduction and exploring theoretical underlying 
structures. It allows the researcher to examine all relationships between individual variables 
(items on a scale), grouping together variables that are correlated in order to extract latent 
factors.  These factors should reflect the underlying processes that have created the 
correlations among variables. “Exploratory factor analysis is usually performed in the early 
stages of research, when it provides a tool for consolidating variables and for generating 
hypothesis about underlying processes.”60 EFA is normally the first step in building scales 
or new metrics.61 Exploratory factor analysis was used in this thesis in an iterative process 
to identify correlations among the 13 potential clinical inertia items that could contribute to 
a clinical inertia scale.  
The following sections 3.7.1 and 3.7.2 outline the assumptions that were explored before 
determining whether the data set was suitable for EFA.  
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 Adequacy of Sample 
Exploratory Factor Analysis requires a robust sample size and a strong correlation among 
variables in the data set.  Adequacy of the sample was verified by the Bartlett´s test of 
Sphericity and the Kaiser-Meyer-Olkin (KMO) measures. The strength of the 
intercorrelations among items (referred to as factorability) was verified by examining the 
correlation matrix. 
Bartlett’s test of Sphericity tests whether the data comes from multivariate normal 
distribution with zero covariances or, in other words, the correlation matrix is an identity 
matrix.  This would indicate that the factor model is inappropriate.  It is appropriate if p < 
0.05.60 The KMO measure of sampling adequacy ranges from 0 to 1.  A minimum value 
suggested for a good factor analysis is 0.6.60  
For a data set to be suitable for EFA, or to achieve factorability, the items in the sample 
must have strong correlations. The correlation matrix was used to identify the value of 
correlations between variables.  Strong correlations are indicated by coefficients greater 
than 0.3.60 
 Data Verification 
The missing values were treated using the exclude case listwise option in SPSS.  With this 
option, cases were included in the analysis only if they had full data on all the variables 
listed for that analysis.   
Normality assessment was performed with the Kolmogorov-Smirnov and Shapiro-Wilk 
tests. The Kolmogorov-Smirnov statistic assesses the normality of the distributions of the 
scores.  A non-significant result (value greater than 0.05) indicates normality.  On the other 
hand, a significant value less than 0.05 suggests a violation of the assumption of normality. 
The Shapiro-Wilk test rejects the hypothesis of normality when the p-value is less than or 
equal to 0.05.   
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 Extraction and Rotation Methods 
The extraction method for this study was the Principal Axis Factors (PAF) technique, 
chosen because the 13 potential clinical inertia items included in the EFA were not 
normally distributed.  Maximum likelihood extraction method is preferred when 
multivariate normality of the variables is observed and PAF for when that assumption is 
violated.61, 62   
Rotations were performed after extraction in an attempt to find the clearest and simplest 
structure for ease of interpretation.  This is achieved by maximizing high correlations 
between factors and minimizing low ones through mathematical procedures.  The types of 
rotations are distinguished in terms of whether they are orthogonal, used when it is believed 
that factors are uncorrelated, or oblique, used when it is believed that the factors are 
correlated.63  According to Osborne, “In the social sciences we generally expect some 
correlation among factors, particularly scales that reside within the same 
instrument/questionnaire, …, and oblique rotation should theoretically render a more 
accurate, and perhaps more reproductible solution.”62 page 33  
In this EFA, the SPSS output for Oblique rotations (correlated items), provided two tables 
of loadings: A Pattern Matrix and a Structure Matrix. The structure matrix disregards the 
fact that the factors are correlated and the differences between high and low loadings are 
more apparent in the pattern matrix. The greater the loading, the more the variable is a pure 
measure of the factor.  Some authors suggest that loadings over 0.71 are excellent, over 
0.63 are very good, over 0.55 are good, over 0.45 are fair and under 0.32 are poor.60 For 
this thesis, based on statistical advice from supervisors, values above 0.40 were considered 
adequate loadings. When no rotation is performed, only one matrix is presented, a Factor 
Matrix. 
 Factor Retention  
The decision on how many of the extracted factors to keep was guided by the scree plot and 
the Kaiser’s criterion (eigenvalue and the total variance explained).  Some authors 
recommend using the scree test in conjunction with the eigenvalues to determine the 
number of factors to retain.61, 62  
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The Scree test involves plotting the eigenvalues of each factor and inspecting the plot to 
find a point where the shape of the curve changes direction or inclination abruptly.  Factors 
that should be retained are those that lie above the point where the line changes 
inclination.64   
The Kaiser’s criterion, or the eigenvalue rule, is the most commonly used technique to 
decide how many factors to retain.64 Using this rule, only factors with an eigenvalue of 1.0 
or higher are retained for further investigation.  The eigenvalue of a factor represents the 
amount of the total variance explained by that factor.   
Once the number of factors was defined, investigation continued with interpreting the 
findings to make clinical sense. This is an essential step in EFA. The interpretation is 
conducted to understand the underlying dimensions that unify the group of variables that 
load on each factor.60  
The strength of the relationship between the factors is measured by the value on the Factor 
Correlation Matrix.  Values above 0.3 are considered strongly correlated.  Values above 0.8 
may be considered, in fact, too highly correlated, suggesting that they are indistinct and 
might actually fit better as a sub-scale of one single factor.65  
One of the most commonly used indicators of internal consistency is Cronbach’s alpha 
coefficient.  Internal consistency for each factor was assessed by checking the coefficient 
value of each factor’s Cronbach’s alpha. Ideally, the Cronbach’s alpha coefficient should be 
above 0.7.64   
3.8 Clinical Inertia Score 
 Factor Score 
A factor score is a useful outcome of EFA.  Factor scores can be calculated in various 
forms.  They are estimates of the scores that subjects would have received on each of the 
factors had it been possible to measure them directly.  The simplest procedure for achieving 
this is to calculate the mean value of each responses in the questionnaire for each 
respondent.60 This method was used to calculate a clinical inertia score which was then 
treated as a continuous outcome variable.   
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3.9 Examining the Relationship between the Clinical Inertia 
Score and Physician Characteristics 
 Bivariate Analysis 
The relationship between the clinical inertia score and physician characteristics was 
examined first using bivariate statistics and then using multiple linear regression.  The 
independent variables used to compare physician characteristics to the factor score were: 
age, sex, years in practice, country of medical degree, practice location (urban or rural), 
Province of practice, practice type (team-based or non-team-based), Diabetes educator 
designation, number of DM patients per week and personal diagnosis of DM.   
Normality for continuous variables and Outcome variable (12-item Score) was assessed by 
Shapiro-Wilk and Kolmogorov-Smirnov tests and verified by examining in the Quartile (Q-
Q) Plots. When distribution of points on the scatterplot form a linear trace, it is presumed 
that the assumption of normality was not violated. 
For the bivariate analysis, the procedures were Pearson correlation for continuous 
independent variables (age, years in practice, number of DM patients per week), 
independent-samples t-test for dichotomous independent variables (sex, practice location, 
country of medical degree, Diabetes educator designation), and ANOVA for categorical 
independent variables with more than two response categories (practice type, Province of 
practice). 
 Multiple Linear Regression 
The primary goal of regression analysis is to investigate the relationship between a 
dependent variable (in this case, the clinical inertia score) and several independent 
variables.  
Standard multiple regression was performed to explore the relationship between the clinical 
inertia factor score and all independent variables in the model. Assumptions underpinning 
multiple linear regression were tested as follows: 
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The adequacy of the sample size was assessed by applying the formula (n ≥ 20 + 5m) 
where m = number of Independent variables (IV).64   
Absence of multicollinearity was determined by examining the correlation matrix and 
variables with a bivariate correlation of 0.7 or more were considered collinear and removed 
from the regression.64 
Absence of Outliers was verified by inspecting the standardised residual scatterplot for 
values beyond ± 3.3.64 
Normality, linearity and homoscedasticity of residuals refer to aspects of distribution of 
scores and the nature of the underlying relationship between variables.  The assumptions of 
linearity and normality were checked by visually inspecting the Normal Probability (P-P) 
Plot of the regression standardised residuals for a reasonably straight diagonal line from 
bottom left to top right, indicating no major deviations from normality.64  
Homoscedasticity was assessed by inspection of the scatterplot.  When the residuals were 
roughly rectangularly distributed with most scores concentrated in the center, it determines 
that the variance of the residuals about the predicted outcome variable scores were the same 
for all predicted scores and the assumption of homoscedasticity was met.64 
The mode ENTER was the model choice, and only entries with full data were included.   
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Chapter 4  
4 Results 
This chapter first describes the sample of family physician respondents. Next, results from 
the Exploratory Factor Analysis are reported.  Finally, the resulting clinical inertia score is 
compared to the characteristics of the family physicians in both bivariate and multivariate 
analyses.   
Important note: Data analysis was processed by SPSS with Brazilian Portuguese 
(European) convention for punctuation, where decimals points are represented by commas, 
not by periods, as in the English convention.  Most tables in this chapter must be read with 
this understanding.   
4.1 Family Physician – Descriptive Results 
One hundred and sixty-two family physician (FP) or primary care physicians (PCP) 
(hereafter referred to as family physicians or FPs) completed the questionnaire.  Table 4-a 
and Table 4-b report on the continuous and the categorical variables respectively. These 
respondents were 56.2% males, 43.8% females with a mean age of 57.5 years. Respondents 
had been practicing medicine for a mean of 26 years. The number of DM patients seen by 
these FP was, on average, 27 DM patients per week. One family physician respondent 
reported seeing an average of 250 DM patients per week.  This respondent also informed 
that he/she is not a diabetes educator and works in a Family Health Team.  That number of 
DM patients/week was deemed highly improbable and was considered an error and it was 
excluded from the analysis. Nine respondents (5.6%) affirmed having a Diabetes Educator 
designation. 
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Table 4-a: Family Physician Respondent Characteristics – Continuous Variables 
 
 
 SD = Standard Deviation; Min = Minimum; Max = Maximum; DM = Diabetes; pt = patient 
The majority, 75.3%, of FPs were in urban areas and 24.7% in rural areas. FPs reported that 
they practiced in Hospitals (4.9%), Family Health Teams (30.9%) or Other settings 
(64.2%). Nine respondents did not specify the type of their practice.  After recoding this 
variable into Hospital, Team-based and not-Team based, the distribution was Hospitals 
(5.4%), Team-based practice (42,3%) and Non-Team-based practice (46.3%). 
Most FP respondents practiced in Ontario (54.7%), Canada’s most populated province.  
The distribution of FP respondents (159 valid responses) across Canada is represented in 
Figure 4-a.  
The majority of respondents obtained their degree in Canada (84.5%).  Fifteen per cent of 
the FP obtained their degree in other countries including respondents from the United 
Kingdom, India, Ireland, South Africa, Slovakia, Uganda, Hong Kong, USA, Jordan, 
Bangladesh, Pakistan and Libyan Arab Jamahiriya.  
Nine percent of the FP respondent had a personal diagnosis of DM, of which 46% reported 
having experienced a diabetes-related hypoglycemic event.   
The distribution for each categorical variable, including re-coded Province and Practice 
type variables, are presented in Table 4-b. 
Mean SD Min
25th 
percentile Median
75th 
percentile Max
Age in years 57.55 9.65 31 50 57 64 85
Years in practice 26 11 3 17 25 33 55
# DM pt/week 27 24 1 12 20 30 101
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Figure 4-a: Distribution of FP Respondents across Canada (%) 
 
 
 Note: Decimals in this graph are represented by commas, not periods. Western/Prairies = British Columbia, Manitoba and 
Saskatchewan; Maritimes = Prince Edward Island, New Brunswick and Nova Scotia  
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Table 4-b: Family Physician Respondent Characteristics – Categorical Variables 
 
Note: Decimals in this table are represented by commas, not periods. N= total number; CDE = Diabetes Educator 
designation; ON = Ontario; QU = Quebec; NL = Newfoundland; AB = Alberta; WP = Western Prairies (British 
Columbia, Manitoba and Saskatchewan); MP = Maritime Provinces (Prince Edward Island, New Brunswick and Nova 
Scotia); DM = Diabetes 
4.2 Exploratory Factor Analysis  
 Adequacy of Sample 
Prior to performing EFA, the suitability of the data for factor analysis was assessed.  
Inspection of the correlation matrix revealed the presence of many coefficients of 0.3 and 
above indicating the factorability of the items (Table 4-c).  The KMO index was 0.923, 
achieving the recommended value of 0.6 or higher, and Bartlett`s test of Sphericity reached 
Count % of N 
Urban 122 75,3%
Rural 40 24,7%
ON 87 54,7%
QU 13 8,2%
NL 18 11,3%
AB 12 7,5%
Western/Prarie 
Provinces
17 10,7%
Maritimes 
Provinces
12 7,5%
Hospital Practice 8 5,4%
Team-based 
Practice
63 42,3%
Not Team-
based Practice
69 46,3%
Missing 9 6,0%
Canada 136 84,5%
Other Country 25 15,5%
Yes 9 5,6%
No 153 94,4%
Yes 14 8,6%
No 148 91,4%
Personal  
DM
Location
Province
Practice 
Type 
Country 
of Degree
CDE
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statistical significance (p < .001), supporting the adequacy of sample size and factorability 
of the correlation matrix (Table 4-d).  
Table 4-c: Correlation Matrix 
 
Note: Decimals in this table are represented by commas, not periods.  
Values > |0.30| considered well correlated 
 
 
Table 4-d: Sample Adequacy tests 
 
 
Note: Decimals in this table are represented by commas, not periods. Sig = Significance 
 
 Data Verification 
The cases were inspected for missing data.  Two cases of missing data were found, where 
respondents chose not to answer a question that was expected to be answered by all 
respondents.  These two cases were excluded from the factor analysis.   
effort
track
progress
advice
increase
monitor 
prepared 
 to help 
time
manag
ement
specific
issue
priority 
routine
help
guideline 
informed
take
initiative
explain
how
manage
discuss
guidelines
solicit
input
motivatio
nal
strategy
professio
nal
liability
effort track progress 1,000
advice increase monitor 0,447 1,000
prepared to help 0,563 0,557 1,000
time management 0,521 0,418 0,645 1,000
specific issue priority -0,061 -0,121 -0,183 -0,172 1,000
routine help 0,550 0,388 0,650 0,575 -0,224 1,000
guideline informed 0,470 0,415 0,551 0,570 -0,118 0,585 1,000
take initiative 0,532 0,488 0,691 0,596 -0,105 0,739 0,628 1,000
explain how manage 0,561 0,461 0,645 0,551 -0,142 0,655 0,545 0,689 1,000
discuss guidelines 0,405 0,397 0,424 0,459 -0,124 0,475 0,477 0,511 0,524 1,000
solicit input 0,531 0,409 0,507 0,517 -0,206 0,491 0,507 0,608 0,571 0,539 1,000
motivational strategy 0,417 0,317 0,485 0,617 -0,048 0,485 0,433 0,579 0,535 0,521 0,581 1,000
professional liability 0,286 0,131 0,300 0,314 0,111 0,302 0,344 0,419 0,265 0,376 0,344 0,404 1,000
0,923
Aprox. Qui-
squared
1076,646
Sig. 0,000
Bartlett` s 
Sphericity  
Test
KMO and Bartlett Tests
Kaiser-Meyer-Olkin Measure 
of sample adequacy
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The Kolmogorov-Smirnov and Shapiro-Wilk statistic tests assess the normality of the 
distribution of scores.  For these tests, the significance value across the table is 0.000, 
suggesting violation of the assumption of normality. Table 4-e reports the test for each of 
the 13 potential items. This result dictated the choice of extraction method as outlined in 
next section, 4.3.1. 
Table 4-e:  Normality Tests 
 
Note: Decimals in this table are represented by commas, not periods. Df = degrees of freedom; Sig = significance 
 
4.3 Factor Analysis – Round 1  
 EFA-1 Extraction and Rotation Methods 
Based on the assessment described in Section 4.2, the data were considered suitable to 
proceed with the EFA. The chosen extraction method was the Principal Axis Factors (PAF) 
technique, due to the observation that there was not a normal multivariate distribution.  
Rotation was performed for achieving a simpler structure, for ease of interpretation.  
Because the 13 potential clinical inertia items were correlated, the oblique technique of 
rotation Oblimin was chosen. The Pattern and Structure matrices report all factor loadings 
Statistic df Sig. Statistic df Sig.
effort track progress 0,253 160 0,000 0,860 160 0,000
advice increase monitor 0,248 160 0,000 0,804 160 0,000
prepared to help 0,274 160 0,000 0,808 160 0,000
time management 0,277 160 0,000 0,849 160 0,000
specific issue priority 0,201 160 0,000 0,901 160 0,000
routine help 0,247 160 0,000 0,870 160 0,000
guideline informed 0,311 160 0,000 0,831 160 0,000
take initiative 0,338 160 0,000 0,815 160 0,000
explain how manage 0,285 160 0,000 0,830 160 0,000
discuss guidelines 0,253 160 0,000 0,874 160 0,000
solicit input 0,289 160 0,000 0,831 160 0,000
motivational strategy 0,281 160 0,000 0,862 160 0,000
professional liability 0,189 160 0,000 0,909 160 0,000
Kolmogorov-Smirnov
a
Shapiro-Wilk
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for each of the 13 potential clinical inertia items on each factor (Table 4-f).  Factor loading 
values of 0.40 and above are considered relevant.  
This first round of Exploratory Factor Analysis revealed the presence of two factors with 
eingenvalues above 1; and one factor with eigenvalue inferior to 1.  The eingenvalues for 
the three factors found were 4.582 (factor #1), 1.356 (factor #2) and 0.824 (factor #3).  It is 
recommended that only factors with eingenvalues of 1 or above should be retained.61 These 
3 factors explained 46.36%, 13.726%, 8.34% of the variance, respectively, and 68.43% 
cumulatively.  Table 4-g presents these results. 
An inspection of the scree plot (Figure 4-b) revealed a break in the inclination of the 
graphic line after the second factor (#2), further corroborating that factor #3 should be left 
out of the analysis.  
Table 4-h reports the factor correlation values in the 3-factor solution, showing a strong 
negative correlation between factor #1 and factor #3 and a weak negative correlation 
between factor #1 and factor #2. Factors #2 and #3 had a weak positive correlation.  
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Table 4-f: Pattern and Structure Matrix for EFA-1 with Oblimin Rotation 
 
Note: Decimals in this table are represented by commas, not periods. Values > |0.40| are considered adequate loadings  
 
Table 4-g: Total Variance Explained EFA-1 
 
Note: Decimals in this table are represented by commas, not periods. 
 
Factor 1 Factor 2 Factor 3 Factor 1 Factor 2 Factor 3
effort track progress 0,666 -0,053 0,074 0,684 -0,548 -0,120 0,475
advice increase monitor 0,603 0,049 -0,064 0,585 -0,403 -0,238 0,348
prepared to help 0,966 0,158 0,026 0,840 -0,563 -0,250 0,716
time management 0,521 -0,254 -0,077 0,733 -0,645 -0,235 0,564
specific issue priority -0,018 0,020 0,563 -0,197 0,049 0,569 0,325
routine help 0,766 -0,022 -0,065 0,801 -0,596 -0,288 0,646
guideline informed 0,557 -0,199 0,009 0,703 -0,615 -0,157 0,512
take initiative 0,735 -0,180 0,094 0,842 -0,726 -0,124 0,738
explain how manage 0,701 -0,107 -0,045 0,793 -0,631 -0,251 0,634
discuss guidelines 0,076 -0,630 -0,132 0,584 -0,690 -0,170 0,501
solicit input 0,134 -0,617 -0,246 0,667 -0,724 -0,301 0,611
motivational strategy 0,117 -0,661 -0,021 0,617 -0,749 -0,072 0,569
professional liability 0,020 -0,570 0,258 0,371 -0,578 0,237 0,398
Pattern coefficients Structure coefficients
Variable Communalities
Rotation 
Sums of 
Squared 
Loadings
Total % of Variance Cumulative % Total
1 4,582 46,362 46,362 4,215
2 1,356 13,726 60,088 2,258
3 0,824 8,342 68,430 0,511
4 0,598 6,049 74,479
5 0,457 4,620 79,099
6 0,403 4,081 83,180
7 0,355 3,588 86,768
8 0,150 3,188 89,956
9 0,303 3,063 93,019
10 0,205 2,074 95,093
11 0,199 2,011 97,104
12 0,155 1,566 98,671
13 0,131 1,329 100,000
Initial Eigenvalues
Factor
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Figure 4-b: Scree plot EFA-1 
 
Note: Decimals in this graph are represented by commas, not periods. 
 
Table 4-h:  Factor correlation Matrix EFA – 1 
 
Note: Decimals in this table are represented by commas, not periods. 
 
 Retaining Factors 
With the support of the results of these tests, it was decided to retain factor #1 and factor #2 
for further investigation.  The third factor was composed of one variable, item #14 of the 
questionnaire.  This variable was separated from the analysis and was the subject of further 
examination, reported at the end of this study. 
Factor 1 2 3
1 1,000 -0,290 -0,747
2 -0,290 1,000 0,026
3 -0,747 0,026 1,000
Factor Correlation Matrix
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4.4 Factor Analysis – Round 2 
 EFA -2 Extraction and Rotation Methods  
A second factor analysis was run, without the one variable that composed factor #3, leaving 
12 items.  In order to maximize high correlations between factors and potential clinical 
inertia items and minimize low correlations between them, rotation was performed and, 
again, the oblique technique Oblimin allowed for a better clustering of items and therefore 
better interpretation.  The rotated solution revealed the presence of simple structure, with 
both factors showing a number of strong loadings predominantly on only one factor on the 
Pattern Matrix.  All factors were internally consistent and well defined by the variables. In 
Table 4-i, good loading values, 0.45 or above, are bolded for ease of interpretation.  
The two-factor solution explained a total of 63.7% of the variance (Table 4-j), with factor 1 
contributing to 52.4% and factor 2 contributing to 11.3%, as shown in the Table 4-j.   
The scree plot on for this second round of factor analysis confirmed the two-factor solution. 
After rotation, the Factor Correlation Matrix, also referred to as Component Correlation 
Matrix (Table 4-k) showed a strong negative correlation between the two factors, at -0.707.   
Internal reliability for each factor was calculated and found to be satisfactory with a value 
of 0.910 for Factor #1 and 0.762 for Factor #2.  The Cronbach Alpha`s value for the 12 
items together was 0.915. (Table 4-l) 
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Table 4-i: Pattern and Structure Matrix for EFA-2 with Oblimin Rotation  
 
Note: Decimals in this table are represented by commas, not periods. Values > |0.40| are considered adequate loadings  
Table 4-j: Total variance Explained EFA-2 
 
Note: Decimals in this table are represented by commas, not periods. 
 
 
 
Factor 1 Factor 2 Factor 1 Factor 2
effort track progress 0,636 -0,074 0,698 -0,605 0,476
advice increase monitor 0,682 0,112 0,790 -0,588 0,369
prepared to help 0,908 0,101 0,836 -0,541 0,705
time management 0,550 -0,251 0,688 -0,523 0,560
routine help 0,748 -0,059 0,828 -0,719 0,625
guideline informed 0,541 -0,222 0,602 -0,370 0,512
take initiative 0,639 -0,267 0,727 -0,639 0,721
explain how manage 0,741 -0,083 0,800 -0,607 0,644
discuss guidelines 0,204 -0,534 0,582 -0,679 0,482
solicit input 0,340 -0,462 0,358 -0,546 0,551
motivational strategy 0,141 -0,661 0,608 -0,761 0,589
professional liability -0,057 -0,587 0,666 -0,702 0,300
Pattern coefficients Structure coefficients
Variable Communalities
Rotation 
Sums of 
Squared 
Loadings
Total % of Variance Cumulative % Total
1 4,543 52,403 52,403 4,336
2 0,979 11,297 63,699 2,439
3 0,602 6,947 70,646
4 0,457 5,266 75,912
5 0,406 4,684 80,597
6 0,355 4,095 84,692
7 0,317 3,660 88,352
8 0,303 3,495 91,847
9 0,215 2,484 94,332
10 0,200 2,312 96,643
11 0,156 1,801 98,444
12 0,135 1,556 100,000
Initial Eigenvalues
Factor
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Figure 4-c: Scree plot EFA-2 
 
Note: Decimals in this graph are represented by commas, not periods. 
 
Table 4-k: Factor Correlation Matrix EFA-2 
 
Note: Decimals in this table are represented by commas, not periods. 
 
Table 4-l: Cronbach`s Alpha EFA -2 
 
Note: Decimals in this table are represented by commas, not periods. 
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Factor 1 2
1 1,000 -0,707
2 -0,707 1,000
Factor Correlation Matrix
Cronbach's 
alpha
Cronbach's alpha 
(standardized 
items)
Number of 
items
Factor 1 0,910 0,910 8
Factor 2 0,762 0,773 4
2-Factor 
solution 0,915 0,921 12
Reliability
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 Factors in EFA - 2 
Table 4-m lists variables that composed factor #1, in order of importance (highest to lowest 
loading values, on the pattern matrix).  
Table 4-m: Loading values (Pattern coefficients) for variables in EFA-2 Factor #1 
 
Table 4-n lists variables that composed factor #2, in order of importance (highest to lowest 
loading values, on the pattern matrix). 
Table 4-n: Loading values (Pattern coefficients) for variables in EFA-2 Factor #2 
 
Although the two factors found were statistically distinguished, they were not clinically 
distinct; they did not describe two different concepts within the overarching theme of 
clinical inertia.  With that in mind, this overlap in construct was discussed with the clinician 
supervisor and we determined that it was appropriate to evaluate the use of a scale with all 
the items as one factor, instead of a two-factor scale. 
 
4.5 Factor Analysis – Round 3 
In Round 3, another EFA was conducted restricting the analysis to one factor. Note that 
with a one-factor solution, there is no rotation. When there are several loadings on the 
factor matrix that have adequate values (greater than 0.40), it is evidence that one-factor 
scale is reasonable.  
Item
I make sure that I am prepared to help my patients manage their hypoglycemia.
helping my patients manage their hypoglycemia is something I do routinely.
I explain how to manage hypoglycemia to my patients.
I advise my patients to increase the frequency of blood glucose monitoring when they are at increased risk for hypoglycemia.
I take the initiative to help my patients improve their hypoglycemia management.
I make an effort to keep track of my patients’ progress with regard to managing their hypoglycemia.
I am confident that I can help my patients manage their hypoglycemia even when there is little time.
the way I help my patients manage their hypoglycemia is informed by current evidence and guidelines.
Loading Value
0.908
0.748
0.741
0.541
0.682
0.639
0.636
0.550
Item
I use motivational strategies to help my patients manage their hypoglycemia.  
My professional liability, according to my specific regulatory body, directs the way I manage patients’ hypoglycemia.
I discuss hypoglycemia-related guidelines regarding driving or operating heavy machinery with my patients.
I solicit patient’ input when discussing their hypoglycemia management.-0.462
Loading Value
-0,661
-0.587
-0.534
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 One Factor Solution – 13 item scale 
This 13-item solution (Table 4-p) explained 50.1% of the variance (Table 4-p). However, 
the item that was found inconsistent in previous EFA-1 for loading on a factor alone, in this 
round of EFA also showed inappropriate loading value, that is, smaller than 0.30. This 
item, #14 “appointment issues take priority”, had a loading value of – 0.174, and it was 
removed from the analysis and therefore not used in the scale.  Another round of EFA was 
run without that item. 
Table 4-o: Factor Matrix EFA – 3 (One-factor, 13-item) 
 
Note: Decimals in this table are represented by commas, not periods.  
Values > |0.40| are considered adequate loadings  
 
Factor
1
effort track progress 0,680
advice increase monitor 0,566
prepared to help 0,792
time management 0,755
specific issue priority -0,174
routine help 0,781
guideline informed 0,715
take initiative 0,839
explain how manage 0,791
discuss guidelines 0,642
solicit input 0,726
motivational strategy 0,681
professional liability 0,431
Factor Matrix
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Table 4-p: Total Variance Explained EFA -3 (One-factor, 13-item) 
 
Note: Decimals in this table are represented by commas, not periods. 
 
4.6 Factor Analysis – Round 4 
 One Factor Solution – 12 item scale 
The fourth iterative round of EFA was a solution with a 12-item scale, excluding the item 
described above in Round 3.  All items loaded on the factor with values superior than 0.40. 
( 
Table 4-q).  This 12-item solution explained 54% of the total variance ( 
 
 
 
 
Table 4-r).  An illustration of the successive iterative rounds of EFA is presented on Figure 
4-d. 
Total
% 
variance
% 
cumulative Total
% 
variance
% 
cumulative
1 6,517 50,129 50,129 6,052 46,554 46,554
2 1,185 9,114 59,242
3 0,868 6,676 65,918
4 0,696 5,351 71,269
5 0,608 4,680 75,949
6 0,557 4,284 80,234
7 0,547 4,207 84,440
8 0,486 3,741 88,182
9 0,436 3,358 91,539
10 0,331 2,549 94,088
11 0,303 2,327 96,415
12 0,252 1,936 98,352
13 0,214 1,648 100,000
Total Variance Explained
Factor
Initial Eigenvalues Sum of Squared loadings 
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Given the clinical sense of this version and the high loadings resulting, the 12 items from 
this 12-item one-factor solution were chosen to create the clinical inertia score as described 
in Section 4.7 below.  
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Figure 4-d: Illustration of the Iterative Process for EFA  
 
EFA = Exploratory factor analysis 
 
Table 4-q: Factor Matrix EFA – 4 (One-factor, 12-item) 
 
Note: Decimals in this table are represented by commas, not periods.  
Values > |0.40| are considered adequate loadings  
 
 
 
Factor
1
effort track progress 0,682
advice increase monitor 0,565
prepared to help 0,791
time management 0,754
routine help 0,778
guideline informed 0,716
take initiative 0,840
explain how manage 0,791
discuss guidelines 0,642
solicit input 0,724
motivational strategy 0,684
professional liability 0,437
Factor Matrix
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Table 4-r: Total Variance Explained EFA – 4 (One-factor, 12-item) 
 
Note: Decimals in this table are represented by commas, not periods. 
 
4.7 Clinical Inertia Score  
A Clinical Inertia Score variable was created by calculating the mean of the response for 
each of the 12 items for each respondent. Descriptive statistics and normality assessment 
for this outcome variable are presented in Table 4-s and Figure 4-ef, respectively.  
Total
% 
variance
% 
cumulative Total
% 
variance
% 
cumulative
1 6,484 54,034 54,034 6,021 50,178 50,178
2 1,007 8,394 62,428
3 0,697 5,805 68,233
4 0,634 5,284 73,516
5 0,569 4,741 78,257
6 0,551 4,593 82,850
7 0,489 4,074 86,924
8 0,437 3,646 90,570
9 0,331 2,762 93,332
10 0,324 2,701 96,033
11 0,256 2,130 98,163
12 0,220 1,837 100,000
Total Variance Explained
Factor
Initial Eigenvalues Sum of Squared loadings 
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Table 4-s: Descriptive Results 
 
Note: Decimals in this table are represented by commas, not periods. N= total number 
 
Figure 4-e: Outcome normality assessment 
 
 
4.8 The Relationship between the Clinical Inertia Score and 
Family Physician Characteristics 
A comparison of the outcome, the Clinical Inertia Score, to physician characteristics was 
performed. 
Valid 160
Missing 2
3,8234
3,8333
0,61140
25 3,5000
50 3,8333
75 4,1667
Percentile
N
Mean
Median
Standard Deviation
Clinical Inertia Score 
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 Bivariate Analysis 
Comparison of the continuous independent variables with the clinical inertia score 
outcome, using Pearson’s correlations coefficient (Table 4-t), showed that none of the 
comparisons achieved statistical significance. 
An independent-samples t-test was conducted to compare the clinical inertia scores for each 
group of respondents in the dichotomous variables of: sex (male/female), practice location 
(rural/urban), country of medical degree (Canada/other countries), Diabetes Educator 
designation (yes/no), personal diagnosis of DM (yes/no). None of the differences in scores 
for these variables achieved statistical significance. Results are presented in Table 4-u. 
Categorical variables with more than two response categories after recoding were analyzed 
using one-way between groups ANOVA with post-hoc tests when appropriate.  Mean, 
minimum, maximum and standard deviation of scores for province and practice type 
categories are presented on Table 4-v and Table 4-w respectively. There was no statistically 
significant association between either province (Table 4-x) or type of practice (Table 4-y) 
and clinical inertia score.   
 
Table 4-t: Correlation for Continuous Variables and Clinical Inertia Score 
 
Note: Decimals in this table are represented by commas, not periods. DM = Diabetes; pt = patient; Sig. = Significance; 
N=total number 
 
score
Years in 
Practice Age
# DM 
pt/week 
Pearson's r 1 0,093 0,066 0,059
Sig. 0,245 0,408 0,46
N 160 157 157 159
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Table 4-u: Clinical Inertia Scores and T-test Results for Dichotomous variables 
 
Note: Decimals in this table are represented by commas, not periods. 
 
Table 4-v: Clinical Inertia Score for Province Categories 
 
Note: Decimals in this table are represented by commas, not periods. Min = Minimum; Max= Maximum; Std Dev = 
Standard Deviation; ON = Ontario; QU = Quebec; NL = Newfoundland; AB = Alberta; WP = Western Prairies (British 
Columbia, Manitoba and Saskatchewan); MP = Maritime Provinces (Prince Edward Island, New Brunswick and Nova 
Scotia) 
 
 
Average
Standard 
Deviation Mínimum Median Maximum Sig.
Male 3,90 0,56 2,42 4,00 5,00
Female 3,72 0,66 1,58 3,83 5,00
Urban 3,82 0,62 1,58 3,83 5,00
Rural 3,84 0,59 2,42 3,83 4,83
Canada 3,81 0,60 1,58 3,83 5,00
Other 
Country
3,87 0,66 2,42 4,00 5,00
Yes 3,97 0,48 3,42 3,75 4,75
No 3,81 0,62 1,58 3,83 5,00
12
-it
em
 s
co
re
Sex
0,067
Practice 
Location
0,760
Country of 
Medical 
Degree
0,640
Diabetes 
Educator 
Designation
0,660
Province Mean Min Max Std Dev
ON 3,792 1,583 5,000 0,646
QU 3,847 2,417 4,833 0,645
NL 3,889 2,833 4,750 0,522
AB 3,958 2,750 5,000 0,769
Western/Prarie 
Provinces
3,975 3,333 5,000 0,468
Maritimes 
Provinces
3,618 2,667 4,167 0,457
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Table 4-w: Clinical Inertia Score for Practice Type Categories 
 
Note: Decimals in this table are represented by commas, not periods. Min = Minimum; Max = Maximum; Std Dev = 
Standard Deviation 
 
 
Table 4-x: ANOVA for Province Variable 
 
Note: Decimals in this table are represented by commas, not periods. df = Degrees of freedom; Z = standard deviation; 
Sig. = Significance 
 
Table 4-y: ANOVA for Practice Type Variable 
 
Note: Decimals in this table are represented by commas, not periods. df = Degrees of freedom; Z = standard deviation; 
Sig. = Significance 
 
 Multiple Linear Regression 
Multiple linear (MLR) regression was used to assess the ability of nine independent 
variables (age in years, years in practice, average number DM patients per week, sex, urban 
or rural practice location, province, personal diagnosis of DM, diabetes educator 
Type of Practice Mean Min Max Std Dev
Hospital 4,094 3,583 5,000 0,533
Team-based 3,858 2,417 5,000 0,564
Not Team-based 3,808 1,583 5,000 0,657
Missing 3,491 2,417 4,083 0,541
Sum of 
Squares
df
Mean 
Square
Z Sig.
Between Groups 1,287 5 0,257 0,682 0,638
Within Groups 56,976 151 0,377
Total 58,263 156
Clinica Inertia Score
Sum of 
Squares
df
Mean 
Square
Z Sig.
Between Groups 1,672 3 0,557 1,518 0,212
Within Groups 52,507 143 0,367
Total 54,18 146
Clinica Inertia Score
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designation, practice type recoded) to predict the score on a Clinical Inertia Scale. This is 
referred to as MLR-1. 
Analyses were conducted on MLR-1 to ensure no violation of the assumptions of 
normality, linearity, multicollinearity and homoscedasticity. Normal Probability (P-P) Plots 
were inspected and the residuals rested well along the line indicating that both normality 
and linearity assumptions were met for MLR-1. 
Multicollinearity was verified by examination of the correlation matrix.  The variable Age 
was highly collinear with variable Years in Practice, with a bivariate correlation of 0.826, 
with statistical significance (p value < 0.001).  
Therefore, the independent variable Age was excluded from the regression and a second 
multiple linear regression analysis (MLR -2) was performed. The correlation matrix for 
MLR-2 is presented on Table 4-z. There was no evidence of multicollinearity for MLR-2. 
The normal Probability (P-P) Plot was inspected and the residuals rested well along the line 
indicating that both normality and linearity assumptions were met for MLR-2 (Figure 4-ff). 
In the Scatterplot examination the standardised residuals for MLR -2 were distributed in a 
rough rectangular shape, indicating that the assumption of homoscedasticity was met ( 
Figure 4-gg). 
After examination of the relationships in MLR – 2, it was observed that none of the 
variables were predictive of the Clinical Inertia Score. ( 
 
 
 56 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4-aa). 
   
Table 4-z: Correlation in MLR -2 
 
Note: Decimals in this table are represented by commas, not periods. Sig.= Significance; N = total number; DM = 
Diabetes; pt = patient; CDE = Diabetes Educator designation 
 
Pearson's 
Correlation
Sig. N
Clinical Inertia Score 1,000 160
Years in Practice 0,093 0,122 157
# DM pt/week 0,059 0,230 159
Sex -0,150 0,029 160
Location 0,019 0,405 160
CDE -0,060 0,227 160
Personal diagnosis DM -0,075 0,174 160
Province (recoded) 0,029 0,358 157
Pratice Type (recoded) -0,151 0,034 147
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Figure 4-f: P-P Plot MLR - 2 
 
Note: Decimals in this graph are represented by commas, not periods. 
Cum Prob = Cumulative Probability 
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 Figure 4-g: Scatterplot MLR -2 
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Table 4-aa: Coefficients MLR – 2 
 
Note: Decimals in this table are represented by commas, not periods. 
Ref = Reference; Avg = average; CDE = Diabetes Educator Designation; DM = Diabetes Mellitus; WP = Western Prairies 
(British Columbia, Manitoba and Saskatchewan); MP = Maritime Provinces (Prince Edward Island, New Brunswick and 
Nova Scotia); Hosp = Hospital; FHT = Family Health Team. 
 
 
Standardized 
Coefficients
B Std Error Beta Lower Limit Upper Limit
(Constant) 4,324 0,67 6,455 0 3 5,648
Years in practice 0,002 0,005 0,044 0,485 0,629 -0,008 0,012
# DM pt/week 0,001 0,002 0,029 0,321 0,749 -0,004 0,005
Sex (Reference=Male) -0,179 0,115 -0,146 -1,559 0,121 -0,406 0,048
Location 
(Reference - Urban)
CDE 
(Reference - Not a CDE)
Personal DM 
(Reference - Do not 
have DM)
Province 
(Reference – Ontario)
Quebec 0,04 0,196 0,018 0,203 0,84 -0,347 0,426
Newfoundland 0,148 0,178 0,076 0,834 0,406 -0,203 0,499
Alberta 0,151 0,196 0,065 0,769 0,443 -0,237 0,538
Western prov inces 0,217 0,175 0,109 1,241 0,217 -0,129 0,563
Maritime prov inces -0,206 0,201 -0,089 -1,024 0,307 -0,605 0,192
Practice Type
(Reference – Hospital)
Family  Health Team 0,013 0,146 0,01 0,089 0,929 -0,276 0,301
Other Practice Type 0,021 0,14 0,017 0,15 0,881 -0,256 0,298
0,184
Model
-0,18 0,184 -0,083 -0,977 0,33 -0,543
0,911 -0,265 0,236
-0,009 0,24 -0,003 -0,036 0,971 -0,482 0,465
Unstandardized Coefficients
t Sig.
Confidence Interval for B 
95,0%  
-0,014 0,127 -0,01 -0,112
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Chapter 5  
5 Discussion  
In this chapter, an overview of the findings is presented and is put into context by situating 
it within the existing literature.  The implications of these findings, and the strengths and 
limitations of this study is also discussed.   Finally, recommendations for future research 
are highlighted. 
5.1 Summary of Findings 
The main contribution of this thesis to the literature is the creation, for the first time, of a 
clinical inertia scale around hypoglycemia management. As a result of multiple iterations of 
factor analysis, it is recommended that the scale be used in the form of a one 12-item scale. 
While sub-scales were identified statistically, there was no conceptual distinction among 
the sub-scales identified, and therefore it is not suggested that they be used without further 
research. The results found in the standard multiple regression analysis showed that, for this 
population, none of the differences in the clinical inertia score found in the family 
physician characteristics variables achieved statistical significance.  The characteristics 
compared to the score were: age, sex, years in practice, average number of DM patients 
seen per week, country of medical degree, practice type, practice location, DM educator 
designation and personal diagnosis of diabetes.   
5.2 Implication of Findings 
A review of recent literature indicates that the management of hypoglycemia in primary 
care setting by family physicians lacks thorough investigation.  In fact, measuring clinical 
inertia in family physicians’ management of hypoglycemia was an absent subject in the 
extensive literature search that anticipated this research. The only available information 
referred to research on similar topics, such as guideline adherence for the care of 
hyperglycemia, clinical inertia related to other chronic problems and other general aspects 
of DM management.  
The major and novel contribution of this study to gain a better understanding of family 
physician management of hypoglycemia, is the development of a practical measure for 
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clinical inertia.  The author believes that development of a clinical inertia score can be an 
important and useful tool for family physicians and primary care services that wish to 
improve the delivery of care to DM patients, specifically in the management of 
hypoglycemia.  It enables medical leaders, service managers and policy makers to assess 
the measurement of clinical inertia in hypoglycemia management in physicians in primary 
care. This in turn will enhance and increase awareness of this under-studied issue in family 
medicine.  Awareness may prompt discussions and reflection about hypoglycemia 
management guidelines.  This may, in turn, precipitate physician behavior modification 
towards critically applying guideline recommendations to their practice and ultimately 
improving outcomes for people with DM. The creation of a clinical inertia measure is a 
novel contribution to the literature on hypoglycemia management that can guide future 
research on the topic of physician behavior influencing management of hypoglycemia in 
primary care settings.   
At this point in the research, no reference values were identified for the scale.  Higher 
scores are intended to reflect less clinical inertia because higher scores reflect more positive 
and proactive behaviors described in the items.  Reference values concerning what 
constitutes clinical inertia will be determined only after testing different populations of 
family physicians and assessing the relationship between the scores and clinical 
hypoglycemia on hypoglycemia management.  
After creating the clinical inertia scale and calculating scores, this study examined potential 
relationships between these scores and family physician characteristics that could be 
associated with the phenomenon of clinical inertia in hypoglycemia management. Findings 
from this analysis diverged from limited existing knowledge in three areas: sex, years of 
practice and working in groups. Lang in 2015, affirmed that males were more prone to 
clinical inertia49, and Sammer in 2008 stated that recent medical school graduates, women, 
minorities, physicians who use computers for information in their practices, and physicians 
in non-solo practice types were significantly less inclined to depart from guidelines.50 Yet, 
this study found no difference in the clinical inertia score results between male or female 
physicians. The existing literature also indicated that physicians with fewer years of 
practice were more likely to follow guidelines50, but the results for the sample of family 
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physicians in this study showed no tendency across years of practice.  The same study by 
Sammer in 2008 50 found that those physicians who worked in groups were more adherent 
to guidelines, and therefore, less clinically inert.  The analyses of the clinical inertia score 
within the practice type variable (Hospital, Team-based or not team-based) did not find 
such disparity in the current study.    
No findings in this study corroborated with the limited existing knowledge on 
hypoglycemia management in primary care that focus on the issue of clinical inertia.  One 
reason for this may be that the majority of the existing studies that examined physician 
behavior towards clinical inertia in management of DM related problems, evaluated other 
aspects of DM care, more consistent with hyperglycemia, such as failure to increase 
pharmacologic treatment in the presence of off-target, elevated A1C hemoglobin.28, 48, 49 
These fundamental differences in the objects of the cited studies and this research made it 
difficult to compare results. 
While this study would need to be replicated in larger and different populations, the new 
evidence generated about clinical inertia around management of hypoglycemia suggests a 
consistency in propensity to clinical inertia behavior across Canadian provinces or whether 
the family physician worked in a rural or urban setting; inertia on the part of the physician 
did not vary inversely to the volume of DM patients seen per week; a designation of DM 
educator was not an advantage in preventing clinical inertia; and a personal diagnosis of 
DM did not lessen nor encourage physician clinical inertia behavior in hypoglycemia 
management. Given that some physician characteristics are not amenable to change, such as 
age, sex, nationality of medical degree and personal diagnosis of diabetes, they do not 
provide opportunities for interventions to change behaviour, and so would be of limited 
practical value in tackling the problem of clinical inertia. Optimistically then, this may 
suggest that other facets of care amenable to change, such as knowledge and support to 
family physicians, may be the most strategic approach for interventions.  
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5.3 Strengths and Limitations 
The strength of this study is that it raises awareness and addresses an issue relevant to 
primary care and family medicine world-wide, that of clinical inertia in hypoglycemia 
management in primary care settings.   
The preference for this statistical method, exploratory factor analysis, allowed for 
observation of underlying constructs where no specific theory was available to explain the 
phenomenon.  This makes it an appropriate choice of statistical analysis for a primer study. 
Data for the analysis were supplied by a major study designed and executed under a 
rigorous scientific method.  Respondents were from across Canada, representing a nation-
wide sample. 
Recognizing possible limitations of this study is key to improving future research.  One 
limitation is that the survey used in this study was based on physicians’ self-report of their 
behaviour and may not reflect actual behavior. Because of the secondary data analysis 
nature of the study’s design, key aspects that could measure clinical inertia were not present 
in the original questionnaire, such as attitudes and behavior of the physician in relation to 
patient’s results on glycemic target or glycosylated hemoglobin levels; or questions about 
the use of electronic medical records, telehealth and other technology-driven clinical 
intelligence tools that could aid physicians in protocols and practice guidelines. Further 
research could investigate and lead to expansion of the clinical inertia scale to include these 
more behavioural components.  
The original question about practice type (“Type of Practice: Hospital, Family Health 
Team, Other: please specify_________”) was not precise enough to classify the team-based 
characteristics of the physician’s practice.  Re-classification was conducted to mitigate this 
problem but the recoding criteria were not free from subjectivity. Practices considered as 
“team based” for the purpose of re-classification were those entries that specifically 
mentioned a team or multi-professional model of care, such as Primary Care Network, 
Long-term and Palliative Care Institutions, Chronic Care Model.  Entries considered as “not 
team-based” were those that did not mention collaborative work with any other health 
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professions such as solo or private practices, clinics comprised exclusively of physicians 
and those that do not mention team work. However, a large number of entries were not 
clear about the professional arrangement in the practice.   In future research employing 
physician surveys, a specific question about team-based practice, along with a clear 
definition of what was being considered a team-based practice should be added to the 
survey to improve the precision for measuring this construct, and perhaps improve the 
prediction power of that item.  
The item that was deleted for loading on a factor by itself, #14 of the InHypo-DM HCP 
questionnaire, “addressing specific appointment issues take priority over discussing their 
hypoglycemia management” refers to demands from the patient that compete for the 
physician’s time and attention during a patient-physician encounter.  This is a problem that 
could explain in part the attitude of the physician for not acting when guidelines would 
indicate an action is in order.51 So while the decision to delete this item from the current 
clinical inertia scale was driven by statistic analysis, conceptually, the presence of 
competing demands is an issue that should be explored in future research in order to better 
understand its contribution to the phenomenon of physician clinical inertia in managing 
hypoglycemia in primary care. 
The interplay between patient and system factors influencing clinical inertia must not be 
ignored.  While this research was designed to understand the role of physician behaviors in 
clinical inertia, future studies should also investigate physician clinical inertia behavior in 
comparison to their patient’s characteristics, such as non-adherence status, A1C levels, 
presence of comorbidity. The knowledge that will derive from such a comprehensive 
understanding of the multi-factorial and complex topic of clinical inertia in primary care 
will undoubtedly improve outcomes for DM patients.  
5.4 Conclusion 
This study is the first of its kind that explores a clinical inertia measurement for 
hypoglycemia management in primary care and, as such, it serves as a primer, a basic 
foundation for future research to test, validate and build upon. The creation of the clinical 
inertia scale for hypoglycemia management is the first step in the development and 
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validation of a scale to measure an important and largely under-studied clinical issue. It is 
hoped that further validation of the scale will happen over time, as it is tested in other 
family physician populations. 
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Appendices  
Appendix A: Recommendations from the 2018 CPG for Hypoglycemia in T2DM  
Reference: Yale, JF et al. Diabetes Canada. 2018 Clinical Practice Guidelines, 
Hypoglycemia. Can J Diabetes. 2018;42(Suppl 1): S1-S325. 
 
1. All people with diabetes currently using or starting therapy with insulin or insulin 
secretagogues and their support persons should be counselled about the risk, 
prevention, recognition and treatment of hypoglycemia. Risk factors for severe 
hypoglycemia should be identified and addressed [Grade D, Consensus]. 
2. The DHC team should review the person with diabetes' experience with 
hypoglycemia at each visit, including an estimate of cause, frequency, symptoms, 
recognition, severity and treatment, as well as the risk of driving with 
hypoglycemia [Grade D, Consensus]. 
3. In people with diabetes at increased risk of hypoglycemia, the following strategies 
may be used to reduce the risk of hypoglycemia: 
a. Avoidance of pharmacotherapies associated with increased risk of recurrent or 
severe hypoglycemia [Grade D, Consensus] 
b. A standardized education program targeting rigorous avoidance of hypoglycemia 
while maintaining overall glycemic control [Grade B, Level 2] 
c. Increased frequency of SMBG, including periodic assessment during sleeping 
hours [Grade D, Consensus] 
d. Less stringent glycemic targets with avoidance of hypoglycemia for up to 3 
months [Grade D, Level 4] 
e. A psycho-behavioral intervention program (blood glucose awareness training) 
[Grade C, Level 3] 
f. Structured diabetes education and frequent follow up [Grade D, Consensus for 
T2DM]. 
4. In people with diabetes with recurrent or severe hypoglycemia, or impaired 
awareness of hypoglycemia, the following strategies may be considered to reduce 
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or eliminate the risk of severe hypoglycemia and to attempt to regain 
hypoglycemia awareness: 
a. Less stringent glycemic targets with avoidance of hypoglycemia for up to 3 
months [Grade D, Level 4] 
5. Mild-to-moderate hypoglycemia should be treated by the oral ingestion of 15 g 
carbohydrate, preferably as glucose or sucrose tablets or solution. These are 
preferable to orange juice and glucose gels [Grade B, Level 2]. People with 
diabetes should retest BG in 15 minutes and re-treat with another 15 g 
carbohydrate if the BG level remains <4.0 mmol/L [Grade D, Consensus]. 
Note: This does not apply to children.  
6. Severe hypoglycemia in a conscious person with diabetes should be treated by 
oral ingestion of 20 g carbohydrate, preferably as glucose tablets or equivalent. 
BG should be retested in 15 minutes and then re-treated with another 15 g glucose 
if the BG level remains <4.0 mmol/L [Grade D, Consensus]. 
7. Severe hypoglycemia in an unconscious person with diabetes: 
a. With no intravenous access: 1 mg glucagon should be given subcutaneously or 
intramuscularly. Caregivers or support persons should call for emergency services 
and the episode should be discussed with the DHC team as soon as possible 
[Grade D, Consensus] 
b. With intravenous access: 10–25 g (20–50 mL of D50W) of glucose should be 
given intravenously over 1–3 minutes [Grade D, Consensus]. 
8. Once the hypoglycemia has been reversed, the person should have the usual meal 
or snack that is due at that time of the day to prevent repeated hypoglycemia. If a 
meal is >1 hour away, a snack (including 15 g carbohydrate and a protein source) 
should be consumed [Grade D, Consensus]. 
9. For people with diabetes at risk of severe hypoglycemia, support persons should 
be taught how to administer glucagon [Grade D, Consensus]. 
Abbreviations: A1C, glycated hemoglobin; BG, blood glucose; CVD, cardiovascular 
disease; CGM, continuous glucose monitoring; CSII, continuous subcutaneous insulin 
infusion; DHC, diabetes health-care team; SMBG, self-monitoring of blood glucose. 
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Appendix B: InHypo-DM HealthCare Provider Questionnaire 
 
 
Investigating Hypoglycemia: Your Perspectives on Diabetes Management Questionnaire 
(InHYPO-DM_HCPQ) 
 
 
Many people with diabetes experience hypoglycemia now and then.  The following series of questions will 
explore your thoughts, feelings, beliefs, and actions around helping your patients manage their hypoglycemia. 
Please be as honest and accurate as possible. There are no correct answers. We are interested in your opinion.  
There are 9 sections in total and other participants have taken 15 minutes to complete the survey. You may refuse 
to answer any question you do not want to answer.  All responses will be kept completely confidential. 
 
 
PLEASE READ BEFORE STARTING: 
Questions will apply to both the treatment and prevention of hypoglycemia. We will refer to this as hypoglycemia 
management, unless specified.   In addition, questions will refer to all “types” of hypoglycemia: mild or moderate 
as well as severe hypoglycemia.  Please refer to the definitions provided below, which describe each of these 
“types” of hypoglycemia. 
Mild or moderate hypoglycemia: When your patient has symptoms of hypoglycemia such as sweatiness, hunger, 
anxiety, weakness, confusion, heart palpitations, difficulty speaking, and/or loses his/her train of thought but is 
still able to take action to reverse these symptoms (for example by drinking a glass of juice, eating something, 
or taking a sugar pill). 
Severe hypoglycemia: When your patient absolutely needs assistance from someone else because he/she is either 
unable to help him/herself or is not aware that he/she needs help. 
 
 
 
 
 
 
 
 
 
SECTION 1 The following questions ask about your understanding of hypoglycemia and its 
management.  Remember that management refers to both treatment and prevention.  
Please select the answer that you believe is true most of the time: 
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SECTION 1 The following questions ask about your understanding of hypoglycemia and its management.  
Remember that management refers to both treatment and prevention.  Please select the answer that you 
believe is true most of the time: 
a) Please rate your level of knowledge: 
  Very low Low Moderate High Very high 
1.) I would rate my level of knowledge about 
hypoglycemia as: 
 
○ ○ ○ ○ ○ 
2.) I would rate my level of knowledge about 
hypoglycemia management as: 
○ ○ ○ ○ ○ 
 
a)  Please indicate your agreement with the following items: 
 
  
In general… 
Strongly 
disagree 
Disagree Neither 
agree nor 
Disagree 
Agree Strongly 
agree 
3.) …I have enough knowledge to help my 
patients manage their hypoglycemia. 
 
○ ○ ○ ○ ○ 
4.) …I know where to go to find information 
about managing hypoglycemia. Examples 
may be printed materials (such as 
guidelines), trusted websites, or 
conferences. 
 
○ ○ ○ ○ ○ 
5.) …I know where I can find support to help 
my patients manage their hypoglycemia. 
Examples may be consulting with another 
healthcare provider or team member, or 
referring a patient to another healthcare 
provider, team member, or care centre. 
 
○ ○ ○ ○ ○ 
6.) …I can access additional training or 
learning programs if I want to in order to 
help my patients manage their 
hypoglycemia.  
 
○ ○ ○ ○ ○ 
 
 77 
 
 
 
 
SECTION 3 These are questions about what you actually do when helping your patients manage 
their hypoglycemia.  Remember that management refers to both treatment and 
prevention. Please select the answer that you believe is true most of the time: 
 
 
 
 
In general, I believe… 
 
Strongly 
disagree 
 
Disagree 
 
Neither 
agree nor 
Disagree 
 
Agree 
 
Strongly 
agree 
7.) …I have the skills to help my patients 
manage their hypoglycemia. 
 
○ ○ ○ ○ ○ 
8.) …I tailor the delivery of my 
hypoglycemia care based on my 
knowledge of my patients’ lifestyles and 
contexts. 
 
○ ○ ○ ○ ○ 
9.) …I am not as good as I could be at 
helping my patients’ manage their 
hypoglycemia. 
 
○ ○ ○ ○ ○ 
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 In general… 
 
 
Never 
 
Rarely 
 
Sometimes 
 
Often 
 
Always 
10.) …I make an effort to keep track of my 
patients’ progress with regard to 
managing their hypoglycemia. 
 
○ ○ ○ ○ ○ 
11.) …I advise my patients to increase the 
frequency of blood glucose monitoring 
when they are at increased risk for 
hypoglycemia. 
 
○ ○ ○ ○ ○ 
12.) …I make sure that I am prepared to help 
my patients manage their hypoglycemia. 
 
○ ○ ○ ○ ○ 
13.) …I am confident that I can help my 
patients’ manage their hypoglycemia 
even when there is little time.  
 
○ ○ ○ ○ ○ 
14.) …addressing the specific appointment 
issue takes priority over discussing their 
hypoglycemia management. 
 
○ ○ ○ ○ ○ 
15.) …helping my patients manage their 
hypoglycemia is something I do 
routinely. 
 
○ ○ ○ ○ ○ 
16.) ...the way I help my patients manage their 
hypoglycemia is informed by current 
evidence and guidelines. 
 
○ ○ ○ ○ ○ 
17.) …I take the initiative to help my patients 
improve their hypoglycemia 
management. 
○ ○ ○ ○ ○ 
18.) …I explain how to manage hypoglycemia 
to my patients. 
 
○ ○ ○ ○ ○ 
19.) 
 
…I discuss hypoglycemia-related guidelines 
regarding driving or operating heavy 
machinery with my patients.   
 
○ ○ ○ ○ ○ 
20.) …I solicit patients’ input when 
discussing their hypoglycemia 
management. 
 
○ ○ ○ ○ ○ 
21.) …I use motivational strategies to help my 
patients manage their hypoglycemia.  
Examples may be praising, encouraging, 
reminding, or warning.  
 
○ ○ ○ ○ ○ 
22.) …my professional liability, according to my 
specific regulatory body, directs the way I 
manage patients’ hypoglycemia.  
 
○ ○ ○ ○ ○ 
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SECTION 4 The following questions ask about what supports you in helping your patients manage 
their hypoglycemia. Remember that management refers to both treatment and 
prevention. Please select the answer that you believe is true most of the time: 
  
 
In general… 
 
 
Strongly 
disagree 
 
Disagree 
 
Neither 
agree nor 
Disagree 
 
Agree 
 
Strongly 
agree 
23.) …I am committed to helping my patients 
manage their hypoglycemia. 
 
○ ○ ○ ○ ○ 
24.) …I know what helps me stay motivated 
to help my patients’ care for their 
hypoglycemia. 
 
○ ○ ○ ○ ○ 
25.) …I believe that I have enough time to 
help my patients manage their 
hypoglycemia.  
 
○ ○ ○ ○ ○ 
26.) …I know how to help motivate my 
patients to manage their hypoglycemia. 
 
○ ○ ○ ○ ○ 
27.) …I have clear goals for managing my 
patients’ hypoglycemia. 
 
○ ○ ○ ○ ○ 
28.) …my goals regarding hypoglycemia 
management align with my patients’ 
goals. 
 
○ ○ ○ ○ ○ 
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SECTION 5 Healthcare providers may differ in their general outlook toward their management of 
hypoglycemia.  We are interested in how you view helping your patients manage their 
hypoglycemia. Remember that management refers to both treatment and 
prevention. Please select the answer that you believe is true most of the time:  
  
 
In general, I believe that… 
 
 
Strongly 
disagree 
 
Disagree 
 
Neither 
agree nor 
Disagree 
 
Agree 
 
Strongly 
agree 
29.) …I share responsibility with my patients 
for helping them manage their 
hypoglycemia. 
 
○ ○ ○ ○ ○ 
30.) …it is my responsibility to society to help 
my patients manage their hypoglycemia. 
 
○ ○ ○ ○ ○ 
31.) …managing hypoglycemia is consistent 
with my professional role. 
 
○ ○ ○ ○ ○ 
32.) …I am optimistic about managing my 
patients’ hypoglycemia in the future.  
 
○ ○ ○ ○ ○ 
33.) …there is not much use in trying to help 
my patients avoid hypoglycemia because 
hypoglycemia will happen anyway.  
 
○ ○ ○ ○ ○ 
34.) …the benefits of helping my patients 
manage their hypoglycemia outweigh the 
effort I put forth. 
 
○ ○ ○ ○ ○ 
35.) …my patients’ health will benefit if I 
help them manage their hypoglycemia. 
 
○ ○ ○ ○ ○ 
36.) ...helping my patients manage their 
hypoglycemia is challenging. 
 
○ ○ ○ ○ ○ 
37.) …my patients adhere to my advice with 
regard to hypoglycemia management. 
 
○ ○ ○ ○ ○ 
38.) …helping my patients’ manage their 
hypoglycemia takes too much of my 
energy. 
 
○ ○ ○ ○ ○ 
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SECTION 6 Healthcare providers may have different ideas about what is and is not supportive 
when it comes to helping their patients manage their hypoglycemia.  Remember that 
management refers to both treatment and prevention. We are interested in 
whether your everyday professional life hinders or supports your ability to help your 
patients manage their hypoglycemia. Please select the answer that you believe is true 
most of the time:  
  
 
In general, to what extent do/does… 
Strongly 
hinders 
Hinders Neither 
hinders 
nor 
supports 
Supports Strongly 
supports 
39.) …your work environment affect your 
ability to help your patients manage their 
hypoglycemia?  
Examples may be materials, staff support, 
etc. 
 
○ ○ ○ ○ ○ 
40.) …the resources provided to you affect 
your ability to help your patients manage 
their hypoglycemia? 
Examples may be from local authorities, 
employers, government, etc. 
 
○ ○ ○ ○ ○ 
41.) …the media affect your ability to help 
your patients manage their 
hypoglycemia?  
Examples may be the news, health 
advertisements, professional networking 
websites, publications, patient 
posters/handouts, etc. 
 
○ ○ ○ ○ ○ 
42.) …your professional role(s) affect your 
ability to help your patients manage their 
hypoglycemia?  
 
○ ○ ○ ○ ○ 
43.) …your scope of practice affect your 
ability to help your patients manage their 
hypoglycemia. 
 
○ ○ ○ ○ ○ 
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SECTION 7 We are also interested in how your social relationships affect your ability to help your 
patients manage their hypoglycemia. Remember that management refers to both treatment and 
prevention. Please select the answer that you believe is true most of the time: 
  
In general, to what extent do/does your 
relationship(s) with…  
 
Strongly 
hinders 
Hinders Neither 
hinders 
nor 
supports 
Supports Strongly 
supports 
44.) …other healthcare providers with 
whom you frequently work affect your 
ability to help your patients manage their 
hypoglycemia?  
Examples may be physicians, nurses, 
pharmacists, etc. 
 
 
○ ○ ○ ○ ○ 
45.) …other healthcare providers in the 
broader professional community affect 
your ability to help your patients manage 
their hypoglycemia?  
Examples may be physicians, nurses, 
pharmacists, etc. 
 
○ ○ ○ ○ ○ 
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SECTION 8 Healthcare providers may experience worry and frustration regarding their patients’ 
risk and management of hypoglycemia. Remember that management refers to both 
treatment and prevention. We are interested in knowing to what extent these 
emotions affect how you help your patients manage their hypoglycemia. Please select 
the answer that you believe is true most of the time:  
  
 
 
 
Strongly 
hinders 
 
Hinders 
 
Neither 
hinders 
nor 
Supports 
 
Supports 
 
Strongly 
supports 
48.) In general, how does your frustration 
about helping patients’ manage their 
hypoglycemia affect your ability to do 
so? 
 
○ ○ ○ ○ ○ 
   
Never 
 
Rarely 
 
Sometimes 
 
Often 
 
Always 
49.) Does this frustration cause you to modify 
against recommended guidelines when 
helping your patients manage their 
hypoglycemia?   
 
○ ○ ○ ○ ○ 
 
a) Frustration about your patients’ hypoglycemia risk and management: 
  
 
 
Strongly 
hinders 
Hinders Neither 
hinders 
nor 
Supports 
Supports Strongly 
supports 
46.) In general, how does worrying about 
helping patients manage their 
hypoglycemia affect your ability to do 
so? 
○ ○ ○ ○ ○ 
  
 
 
Never 
 
Rarely 
 
Sometimes 
 
Often 
 
Always 
47.) Does this worry cause you to modify 
recommended guidelines when helping 
your patients manage their 
hypoglycemia?   
 
○ ○ ○ ○ ○ 
 
a) Worry about your patients’ hypoglycemia risk and management: 
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SECTION 9 This section contains questions related to your background and management of 
patients’ mild/moderate or severe hypoglycemia events .   
1. Sex:  
 
 
2. Year of birth: _________ 
 
3. Location of practice:  
 
                
 
 
4. Location of practice:  
 
Province (pick from the list): (ON, QC, NS, NB, MB, BC, PE, SK, AB and NL) 
 
5. Type of practice: 
 
 
 
 
 
6. What is your current profession?  
 
 Endocrinologist  
 Internal Medicine 
 Family Physician – Diabetes Specialist 
 Family physician 
 Nurse practitioner 
 Pharmacist 
 Nurse 
 Dietitian 
 Other ______________________ 
 
7. Are you a diabetes educator? 
 
  
  
 
8. How long have you been practising in your current role (years)? ____________________________ 
 
 
 
9. Where did you obtain your most recent professional degree? 
 
Type in name of country: ________________________________________ 
 
Male   
Female   
Urban   
Rural   
Hospital   
Family Health Team   
Other, please specify: ____________________________ 
Yes   
No   
 85 
 
 
 
1. How many people with diabetes do you see in an average week? 
Type in the number of people: ____________ 
 
2. Of these people, approximately what proportion have been diagnosed with Type 1 diabetes 
Type in the percentage of people: ____________ % 
 
3. Of these people, approximately what proportion are taking medication for their diabetes that risks 
hypoglycemia (for example insulin or sulyphonureas)? 
Type in the percentage of people: ____________ % 
 
4. Have you been diagnosed with diabetes? 
 
 
 
 
5. Have you ever experienced a diabetes-related hypoglycemia event? 
 
 
 
6. Do you want to be entered in a drawing to win a prize? 
 
      
7. If yes, please enter your email address below so that you can be included in a drawing for a prize. 
This information will not be associated with your survey responses. 
              Email address  
 
Yes   
If yes, Type 1   
 Type 2   
No   
Yes   
No   
Yes   → Q 15. 
No   →End of Survey 
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